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Abstract
Hemophilia A is the most common, inherited severe bleeding diathesis and is due to a deficiency of functional
Factor (F) VIII. Two challenges to current FVIII replacement therapy are maintaining sustained FVIII
corrections and treating the 30% population of Hemophilia A patients who develop FVIII inhibitors. Gene
therapy promises to be an attractive treatment for hemophilia A as there is a wide therapeutic window for
FVIII corrective plasma levels. Since platelets target to hemostatic injuries, ectopically expressed platelet (p)
FVIII is an attractive alternative FVIII delivery strategy. We have already shown the effectiveness of platelet
human B-domainless factor VIII (phBF8) in the presence of circulating inhibitors in FVIIInull mice.
However, the clots formed are unstable and lead to increased embolization with phBF8. This dissertation
describes platelet-specific gene therapy using three FVIII variants with enhanced activity: inactivation
resistant FVIII (IR8), canine (c) B-domainless FVIII (cBF8), and hBF8R1645H. Each improved clotting
efficacy in FVIIInull mice and decreased embolic risk though to different degrees. For example, we found that
despite pcBF8 having ~30% antigenic levels of phBF8, it corrected clot instability seen in a cremaster injury
model in FVIIInull mice. Since IR8 does not bind FVIII carrier protein, Von Willebrand Factor (vWF),
efficiently, we tested the effectiveness of this variant in the presence of circulating FVIII inhibitors, and found
that vWF binding was not needed for IR8 to be effective. To understand the cellular mechanism for decreased
cBF8 relative to hBF8 expression level in megakaryocytes, we studied mRNA levels and the effect of pcBF8
on megakaryopoiesis and found that the level of cBF8 is related to increased cellular apoptosis. Finally to
understand the mechanistic basis of pcBF8 increased hemostatic effectiveness, we examined whether
mutation of the cleavage site for the Golgi apparatus enzyme PACE/furin in hBF8 to that of cBF8, which
increases the FVIII’s activity, would also enhance hBF8R1645H pFVIII activity and affirm that this occurs.
These studies provide new insights into pFVIII during megakaryopoiesis and how to optimize pFVIII
hemostatic efficacy that should be useful in translating this therapeutic model to a large animal hemophilia A
model and future clinical trials.
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UNDERSTANDING AND IMPROVING PLATELET-DELIVERED FACTOR (F) 
VIII HEMOSTATIC EFFICACY IN HEMOPHILIA A MICE 
 
Teshell K. Ponteen Greene 
Mortimer Poncz 
 
Hemophilia A is the most common, inherited severe bleeding diathesis and is due to a 
deficiency of functional Factor (F) VIII. Two challenges to current FVIII replacement 
therapy are maintaining sustained FVIII corrections and treating the 30% population of 
Hemophilia A patients who develop FVIII inhibitors. Gene therapy promises to be an 
attractive treatment for hemophilia A as there is a wide therapeutic window for FVIII 
corrective plasma levels. Since platelets target to hemostatic injuries, ectopically 
expressed platelet (p) FVIII is an attractive alternative FVIII delivery strategy. We have 
already shown the effectiveness of platelet human B-domainless factor VIII (phBF8) in 
the presence of circulating inhibitors in FVIIInull mice. However, the clots formed are 
unstable and lead to increased embolization with phBF8. This dissertation describes 
platelet-specific gene therapy using three FVIII variants with enhanced activity: 
inactivation resistant FVIII (IR8), canine (c) B-domainless FVIII (cBF8), and 
hBF8R1645H. Each improved clotting efficacy in FVIIInull mice and decreased embolic risk 
though to different degrees. For example, we found that despite pcBF8 having ~30% 
antigenic levels of phBF8, it corrected clot instability seen in a cremaster injury model in 
FVIIInull mice. Since IR8 does not bind FVIII carrier protein, Von Willebrand Factor 
(vWF), efficiently, we tested the effectiveness of this variant in the presence of circulating 
FVIII inhibitors, and found that vWF binding was not needed for IR8 to be effective. To 
understand the cellular mechanism for decreased cBF8 relative to hBF8 expression level 
in megakaryocytes, we studied mRNA levels and the effect of pcBF8 on 
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megakaryopoiesis and found that the level of cBF8 is related to increased cellular 
apoptosis. Finally to understand the mechanistic basis of pcBF8 increased hemostatic 
effectiveness, we examined whether mutation of the cleavage site for the Golgi apparatus 
enzyme PACE/furin in hBF8 to that of cBF8, which increases the FVIII’s activity, would 
also enhance hBF8R1645H pFVIII activity and affirm that this occurs. These studies 
provide new insights into pFVIII during megakaryopoiesis and how to optimize pFVIII 
hemostatic efficacy that should be useful in translating this therapeutic model to a large 
animal hemophilia A model and future clinical trials. 
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Chapter 1 
 
Introduction 
 
1.1 Background 
1.1.1 Hemophilia A 
Hemophilia A is a monogenic congenital bleeding disorder resulting from a deficiency of 
the Factor (F) VIII gene product, and occurring at a frequency of 1:5000 live male births 
(24, 67). It is a well-known disease in mankind’s history; however, the genetics of this 
disease was not fully described until the early 1800s. The first account of hemophilia 
dates back to the 2nd century AD in the Talmud when three babies from three Jewish 
sisters died after being circumcised (147). It was recognized that a woman transfers the 
disease to her son regardless of the father. Early investigators attributed hemophilia to 
be a disorder of the vascular system, however, by the early 1900s; Sahli who had 
observed a prolongation of clotting times raised questions in reference to this conclusion 
(156). This idea was tested and confirmed a few years later in 1911 by Addis (1), who 
showed that one could correct the clotting time in hemophilic blood by adding normal 
plasma, and for this reason diagnosing the disease a qualitative abnormality of thrombin 
generation. Almost twenty-fives years later, Patek and Taylor described the role of FVIII 
in hemostasis, and called the missing factor an “anti hemophilic globulin”. 
Hemophilia A results from a loss of FVIII activity associated with a wide variety 
of mutations within the FVIII gene due to the large size of the gene product. These 
mutations can be categorized into base pair deletional mutations, insertions, 
substitutions, and FVIII gene rearrangements. Almost half of all severe hemophilia A 
cases result from prevalence for intron 22 inversion within the FVIII gene (82, 113). 
Related to the residual activity of FVIII, the severity of the disease ranges from a mild 
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phenotype corresponding to a 5-30% of normal FVIII activity and affecting 15% of 
patients. 25% of patients have a moderate phenotype with activity levels of 1-5%, and 
60% of patients have the most severe form of hemophilia, with <1% FVIII activity (3). 
Severe patients experience recurring spontaneous bleeds into their joints, muscles, and 
inner organs leading to chronic synovitis, weakening of muscles around the joint, and 
loss of joint support (42). A subpopulation of severe patients experience hemorrhaging 
in the central nervous system, which accounts for 20% of resulting in death from 
hemophilia A (47). Additionally, the formation of antibodies against FVIII is restricted to 
severe patients and occurs in about 30% of this patient population (193).  
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1.1.2 Coagulation Factor VIII  
1.1.2.1  Primary Structure 
Coagulation FVIII is a large plasma glycoprotein that is essential for formation of blood 
clots. The FVIII gene has been mapped to the X-chromosome at Xq28, and spans 186 kb 
of genomic DNA. Human and animal transplantation studies of FVIII suggest that FVIII 
is mainly synthesized in the rough endoplasmic reticulum (ER) of the liver (191), spleen 
(88), and endothelial cells (EC) (52, 64). The earliest description of the structural 
components of FVIII was in the early 1980s, not too long after the gene was first cloned. 
The FVIII gene consists of 26 exons ranging in size from 69 bp to 3,106 bp, and 
codes for a 9 kb mRNA spliced sequence. Upon translocation to the lumen of the ER, 
FVIII single-chain peptide is cleaved to produce a 2,351 amino acid mature protein 
consisting of 3 A-domains, 2 C-domains and a large B-domain 0f 980 amino acids. The 
size of the A1, A2 and A3 domains are 336, 345 and 335 amino acids respectively; the C1 
and C2 domains are 155 and 152 residues, respectively. Acidic regions within the A 
domains are a1, a2 and a3, and have been shown to be important in regulating FVIII 
activity and interaction with other proteins. The resulting FVIII protein is in an A1-a1-
A2-a2-B-a3-A3-C1-C2 orientation (177, 182) as shown in Figure 1.1. Once secreted, FVIII 
is further processed into a copper ion (Cu+2) stabilized heterodimer consisting of a 90-
200 kD heavy chain of domains A1-a1-A2-a2 with the B domain, and a 80 kD light chain 
of domains a3-A3-C1-C2 (70, 177, 182) as denoted in Figure 1.1.  
The A domain of FVIII has homology to the triplicate A domains in 
ceruloplasmin (77), a Cu+2 binding protein, and coagulation FV (65). Site-directed 
mutagenesis of cysteine residue 310 within the type-1 Cu+2 binding site of the A1 domain 
supports a direct interaction of A1 domain and copper, as this mutation resulted in a loss 
of activated FVIII (FVIIIa) function and a disassociation of secreted heavy and light 
chains (170). The interaction between FVIII and FIXa for a procoagulant effect involves 
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association through the A2 domain. The C domain exhibits homology to milk fat globule 
protein and discoidin 1, two proteins that are known to bind glycoconjugates and 
negatively charged phospholipids (141, 168). Several studies have confirmed that 
hydrophobic regions within the C2 domain are important for phosphatidyl serine (PS) 
and Von Willebrand Factor (vWF) binding (43, 84), and FVIIIa light chain is known to 
bind phospholipid vesicles with a higher affinity than the C2 domain (154). A recent 
study proposed that the C1 domain contributes to platelet binding, as C2 domain 
blockage did not abolish the binding of recombinant C1C2 proteins to activated platelets 
(60). In fact it was found that there was a 4-to 5 fold greater binding sites per activated 
platelet for the recombinant C1C2 protein compared to the C2 protein. A follow up in 
vitro study demonstrated that FVIII without the C2 domain results in a marked 
reduction in platelet binding, but still has the capacity to bind phospholipid membranes, 
supporting a direct role for the C1 domain in this interaction (186). 
 The B domain is coded by a single large exon 14. It spans the FVIII sequence from 
amino acid 741-1648, and unlike the other domains, has no known homology to any 
other proteins. The B domain contains 19 of the 25 asparagine (N)-linked glycosylation 
sites within the entire FVIII protein (183). Studies have shown that the B domain is not 
directly required for FVIII procoagulant activity (31, 69, 178), and that removal of this B 
domain increases FVIII mRNA and protein levels (137, 139). Moreover, it has recently 
been shown that the B domain is important for FVIII intracellular processing and 
secretion (102). 
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Figure 1.1: Coagulation FVIII domain structure and processing. Top, the 
initial translated FVIII protein is shown. It contains three distinct domain structures: 
3 A domains, 2 C domains, and a single gylcosylated B domain. Prior to FVIII 
secretion from the cell the B domain is cleaved, generating the heavy and light 
chains. This inactive FVIII heterodimer circulates in the plasma bound to von 
Willebrand Factor (vWF). The complex involved in blood coagulation FVIIIa is 
shown after FIIa cleavage. Inactivation occurs by A2 domain disassociation (“I”) and 
by further proteolytic digestion by FIIa, FXa or activated Protein C (aPC) (“II”).  
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Secreted FVIII has a half life of ~10 hrs (172) and circulates in the plasma at a 
concentration range of 100-200 ng/ml (98), in a non-covalent complex with its carrier 
protein vWF (114) through the acidic a3 domain of FVIII. vWF not only serves as FVIII 
carrier, but also helps to regulate FVIII activity by preventing FVIII binding to 
phospholipids (202) and activated platelets (55), as well as protecting FVIII from 
proteolytic degradation by activated Factor X (FXa) and the activated Protein C (aPC) 
complex (32, 57, 129). Moreover, vWF supplies a high concentration of FVIII to sites of 
vascular injury by indirectly binding platelets to the sub endothelium. FVIII is fully 
activated by thrombin (FIIa) following cleavage at three arginine (R) sites: R372, R740 to 
release the heavily glycosylated B domain, and R1689 for dissociation from vWF, to 
generate a FVIIIa heterotrimer (33, 138). This FVIIIa heterotrimer is very unstable and 
rapidly undergoes spontaneous inactivation by dissociation of the A2 domain, and by 
further proteolytic digestion by FIIa, Xa and aPC (34, 122) as shown in Figure 1.1 
 
 
1.1.2.2 Intracellular Proteolytic Processing 
Hepatocytes (191) and EC (52, 64) are believed to be the primary sites of FVIII 
production. However, because of the tendency of FVIII to be expressed at very low 
yields, it has been difficult to establish a primary cell line that expresses FVIII. The 
transfection and expression of FVIII cDNA in several mammalian cells has allowed 
identification of the post-translation processing and secretion of FVIII (54, 136). 
Immediately following synthesis, FVIII is translocated to lumen of the ER where 
the single chain peptide is cleaved to produce the 2351 amino acid FVIII protein. In the 
ER the first modification of FVIII is the addition of a 14-branched high mannose-
containing oligosaccharides chain to several asparagine (N) residues mainly within the B 
domain of FVIII as displayed in Figure 1.2, and subsequent trimming of these residues 
  
 
7 
by glucosidase I and II. This allows for the stabilization of the folded domains and 
interaction of FVIII with ER chaperone proteins immunoglobulin binding protein (BiP), 
and two lectin proteins calnexin (CXN) and calrectulin (CRT). The calnexin/calreticulin 
(CXN/CRT) cycle promotes folding of glycoproteins and retains non-native glycoproteins 
in the ER until they are correctly folded (29). The full CXN/CRT trimming cycle involves 
the enzymatic removal of three glucose units from the 14-subunit oligosaccharides that 
are attached to the asparagine residues for FVIII release from the two lectin proteins. 
Correctly folded FVIII undergoes disulfide bond formation and can exit the ER, while 
unfolded and or mis-folded FVIII reinters the trimming cycle for proper folding or 
becomes degraded. A fraction of FVIII also binds to ER stress protein BiP. This protein 
can be induced by the inhibition of N glycosylation, the mis-folding of proteins in the ER 
and increases in the levels of FVIII. FVIII dissociation from BiP and secretion requires 
high levels of intracellular adenosine triphosphate (ATP) (28). A single amino acid 
mutation at phenylalanine (Phe) residue 309 to serine (Ser) within the BiP binding site 
results in an increased FVIII secretion by several folds and a reduction in ATP 
requirement for secretion (169).  
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Figure 1.2: Intracellular trafficking processes of FVIII (from Steve W. Pipe 
(132)). Newly synthesized FVIII is translocated to the lumen of the endoplasmic 
reticulum (ER). In the ER, FVIII undergoes glycosylation of the N-linked sites within the 
B domain, allowing for proper folding via the calnexin/calrectulin (CXN/CRT) trimming 
cycle. Folded FVIII exits the ER and is transported to the Golgi apparatus via vesicular 
transport of the cargo receptor binding proteins mannose-binding lectin 1 (LMAN1) and 
the multiple coagulation factor deficiency 2 (MCFD2). In the Golgi, FVIII is further 
processed, leading to cleavage of the single chain peptide into a heavy and light chain 
and secretion from the cell.  
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Properly folded FVIII binds to a cargo-specific receptor complex consisting of the 
transmembrane protein mannose-binding lectin 1 (LMAN1 also known as ERGIC-53) 
and its binding partner, the multiple coagulation factor deficiency protein 2 (MCFD2) as 
shown in Figure 1.2. This FVIII becomes packaged into vesicles and is transported from 
the ER to the Golgi apparatus via vesicle-mediated transport. Mutations within the 
LMAN1 or MCFD2 that results in a loss of function or binding interaction with either 
protein have been shown to cause the coagulation defect of combined FV and FVIII 
deficiency (199). This disorder is associated with low plasma levels of FV and FVIII 
ranging from 5-30%, and appears to be an N oligosaccharide dependent defective 
secretion of FV and FVIII from the ER (110).  
Once in the Golgi FVIII undergoes further processing including the modification 
of N-linked high-mannose oligosaccharides to complex structures, O-linked 
oligosaccharides attachment to serine/threonine residues within the B domain, and 
sulfation of tyrosine residues within regions of FVIII characterized by acid residues in 
the heavy and light chain. This post-translational modification of tyrosine occurs 
frequently in proteins that interact with thrombin (68). The six sites of sulfation within 
FVIII are required for full FVIII activity as mutations of several tyrosine residues to 
phenylalanine is known to reduce the rate of thrombin cleavage and activation (103). The 
final step in FVIII processing prior to secretion is intracellular proteolysis of the R-X-X-
R motif within the B domain to produce the heavy and light chains of FVIII. This process 
occurs by cleavage at R residues 1313 and 1648 by the paired amino acid cleavage 
enzyme (PACE/furin). Although the B domain of FVIII is partially cleaved during this 
process, a substantial amount of the B domain is secreted as part of the unactivated 
circulating FVIII heterodimer.  
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1.1.2.3 Cofactor Activity 
Blood coagulation is the physiological response to vascular injury aimed at preventing 
excessive bleeding. It is regulated by a series of serine-protease dependent proteolysis 
reactions that occurs on negatively charged phospholipid surface of activated platelets. 
As indicated in Figure 1.3 there are numerous feed-forward loops that ultimately mediate 
a localized thrombin burst, leading to fibrin stabilization of platelet plug formation, and 
consequently the cessation of bleeding. FVIII is a critical component of the intrinsic 
pathway involved in this process as highlighted in Figure 1.3.  
Following vascular damage, tissue factor (TF) is exposed to blood. The 
interaction of activated factor VII (FVIIa) on TF bearing cells promotes the first traces of 
FXa. FXa serves as a cofactor for activated Factor V (FVa) to yield the prothrombinase 
complex (FXa:FVa). This initiation phase of coagulation permits the cleavage of 
prothrombin (FII) to FIIa, to generate small traces of thrombin. FIIa is the central 
regulatory factor in this complex pathway and can activate FVIII, FV, FIX and platelets. 
FVIIIa functions as a non-enzymatic cofactor for the serine protease FIXa to increase its 
catalytic activity by 4-5 orders of magnitude (144). This membrane bound complex with 
FX forms the tenase complex (FVIIIa:FIXa:FX), allowing for the propagation of 
coagulation through the activation of FX, for an efficient production of thrombin and the 
cleavage of fibrinogen into fibrin for adequate hemostasis. 
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Figure 1.3: The role of FVIIIa in the intrinsic coagulation cascade. Blood 
coagulation is mediated by a number of proteolytic processes on the negatively charged 
phospholipid surface of activated platelets that ultimately results in the formation of a 
fibrin clot. Initiation begins with TF generated FXa producing small traces of FIIa. FIIa 
is the key regulator in this cascade and can activate FVIII, allowing for FVIIIa to interact 
with FIXa and FX forming the tenase complex. FVIIIa increases the catalytic activity of 
FIXa, thereby accelerating the interaction of FXa:FVa and the propagation of fibrin 
generation and the cessation of bleed.  
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1.1.3 Platelets and Hemostasis 
Platelets are the smallest cellular component of blood ranging in size of 2-5 µm, and 
circulating for 7-10 days in the blood stream (94). They are anucleated fragments 
liberated from bone marrow megakaryocytes during the process of thrombopoiesis. The 
mechanism of platelet production by megakaryocytes has significantly evolved in recent 
years. Early studies proposed that platelets are produced by cytoplasmic fragmentation 
(109, 201); however recent evidence supports a flow model of platelet assembly that 
incorporates the cytoplasmic fragmentation model (62, 76, 128). This model suggests 
that the process of platelet release occurs from the end of megakaryocyte extensions off 
the tip of proplatelets. Proplatelets are 250-500 µm pseudopod like structures that 
extends from the body of the megakaryocyte (128). These pro-platelets act as an 
assembly line with a platelet being produced at the end of each pro-platelet. The average 
platelet count in humans ranges from 150-400 x 109 per liter of blood (159). 
Circulating platelets maintain a compact discoid shape with a very complex 
cytoplasm. The subcellular compartment of a platelet contains 3 distinct secretory 
organelles: dense (δ) granules, alpha (α) granules, and lysosomes (λ granules). Platelet 
granules contain a wide assortment of proteins that are accumulated by megakaryocyte 
synthesis and endocytosis of plasma proteins. Once platelets are activated, the contents 
of these granules are released and can partake in a range of physiological and 
pathological processes including hemostasis, wound healing and vascular remodeling. 
The δ-granules contain serotonin, adenosine nucleotides ATP and ADP and divalent 
cations Mg+2 and Ca+2, while the α-granules contains a much broader spectrum of active 
proteins such as vWF, FV, and the abundant platelet-specific C-X-C motif chemokine 
ligand 4 (CXCL4) also known as Platelet Factor 4 (PF4) (16). 
A variety of receptor glycoproteins important for platelet activation, adhesion, 
and signaling are located on the platelet surface and its open canalicular space (OCS). 
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The two most abundant receptors are the vWF receptor complex Glycoprotein Ib-IX-V 
(GPIb-IX-V, CD42) and the integrin fibrinogen receptor GPIIb-IIIa (αIIb-β3, CD41a). 
The GPIb-IX receptor is one of the most abundant platelet proteins with ~25,000 copies 
per platelet (21). It is important in mediating platelet adhesion to the sub-endothelial 
matrix, EC, leukocytes, and indirectly to collagen. Bernard Soulier disease is caused by 
mutations within the gene that codes for this receptor, and results in large platelets with 
defective adhesion, mild thrombocytopenia, and the inability of platelets to bind vWF (6, 
7). The linkage of platelets to each other to form a platelet plug is mediated by the 
binding of fibrinogen and vWF to the αIIb-β3 receptor (5, 140). The α chain is expressed 
almost exclusively on platelets, while the β subunit is expressed on other cell types. There 
is ~80,000 αIIb-β3 receptor sites per platelet surface (121), with sites in the OCS, on the 
membrane of α-granules, as well as on the platelet surface. Glanzmann thrombasthenia 
is cause by mutations within the gene for this receptor complex and results in decreased 
platelet fibrinogen binding (53, 200). 
Platelets are central to maintaining hemostasis (161). Under normal physiological 
conditions, the intact endothelium helps to maintain blood fluidity in part by acting as a 
barrier that prevents platelet activation. This is mediated by the EC monolayer that 
separates platelets and platelet activating molecules that are embedded in the vessel 
wall, and by the release of prostacyclin I2 and endothelium derived relaxing factor (nitric 
oxide), two potent vasodilators and direct inhibitors of platelet activation (108, 181). The 
formation of a stable platelet plug involves three distinct phases: the initiation phase, the 
extension phase and the perpetuation phase (13).  
The initiation stage involves the arrest and eventual activation of moving 
platelets by the two sub-endothelial adhesive substrates collagen and vWF. This receptor 
mediated process is regulated by the adherence of platelets to the exposed collagen 
following injury via the platelet receptors GPVI (80) and the integrin α2β1 (150). 
  
 
14 
Following adhesion the indirect binding of collagen to vWF via the GPIb-IX-V receptor 
complex on platelets allows for the firm binding of platelets to the damaged vessel wall 
(190), leading to full platelet activation and the formation of a platelet monolayer. 
Activated platelets undergo morphological changes, and release their granular contents 
(120). The extension phase involves the release and accumulation of ADP and Ca+2 from 
δ-granules, and the platelet-derived agonist thromboxane A2 from activated platelets to 
amplify the activation and recruitment of other platelets to the site of vascular injury. 
This phase also requires the activation of the αIIb-β3 receptor for binding of fibrinogen 
and vWF to promote platelet/platelet cross-linking. The perpetuation or stabilization 
phase of platelet formation is controlled by the ability of platelets to interact with each 
other long enough to cause secondary signaling effects downstream of platelet clustering 
(13). The localized production of thrombin during the initiation stage of coagulation as 
described in the previous section permits for the activation and recruitment of more 
platelets to the site of injury. These activated platelets provide an anionic phospholipid 
surface for the assembly of the tenase and prothrombinase complex for the propagation 
of the simultaneously ongoing coagulation cascade. The final outcome is formation of a 
stable mature clot and hopefully cessation of bleeding at the injured site.  
 
 
1.2 Clinical Challenges of Hemophilia A Therapy  
In the mid-last century, significant hemophilia A bleeding episodes were primarily 
treated with whole blood transfusions (47). However, once human plasma was 
fractionated, plasma-derived FVIII became the choice of therapy (47) until the concerns 
of infectious complications, especially from the human immunodeficiency virus (HIV) 
and the hepatitides lead to recombinant products. In the late 1980s once FVIII was 
cloned (182) and full-length recombinant FVIII (rFVIII) was expressed, rFVIII became 
  
 
15 
the main replacement therapy for hemophilia A (153). rFVIII therapy controls ~80% of 
joint bleeding episodes after a single dose (14, 90, 160); nonetheless, because the half-life 
of infused FVIII is the same range of endogenous FVIII, it must be given on a frequent 
basis as replacement or as prophylaxis where it is often given three times a week (12). 
rFVIII therapy is even more costly than plasma-derived products (36). In the 30% of 
hemophilia patients who develop inhibitors to FVIII (11, 59, 193), replacement therapy 
can be problematic and quite expensive (74). Patients with inhibitors are now treated 
with alternative therapeutic agents such as activated plasma-derived products that 
bypass FVIII inhibitor (176), and with coagulation factors such as rFVIIa (23) that 
bypasses the need for FVIII in coagulation. However, since FVIIa has a half-life of 2 
hours in the circulation, is very expensive and patients can be recalcitrant to this form of 
therapy (73, 95). 
 
 
1.3 Novel Approaches for the Treatment of Hemophilia A  
1.3.1 Improving FVIII  
Unlike many other proteins of similar size, expression of FVIII in mammalian cells is 
inefficient (91). This is a reflection of relatively low expression of FVIII mRNA, the mis-
folding and ultimate degradation of the primary translated product (69, 91), and the 
retention of FVIII within the ER through interaction with various chaperone proteins 
such as BiP through the A1 domain of FVIII (27, 135). Designing FVIII variants with 
improved efficiency of FVIII mRNA levels, increased FVIII secretion, increased FVIII 
potency, and prolonged half-life as summarized in Figure 1.4 can increase the success of 
gene therapy in hemophilia A patients.  
Attempts at improving the intracellular processing of FVIII have shown promise 
as a new treatment therapy. The first improvement in FVIII levels was observed with a 
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variant that had the heavily-glycosylated B domain deleted (hBFVIII). This variant 
possesses the same biological activity as full length FVIII (69, 146). A meta-analysis of 13 
studies reporting the incidence of bleeding under prophylaxis and the half-life of full-
length FVIII and hBFVIII, suggests that hBFVIII is less effective than full-length FVIII 
and has a shorter half-life as well (50). An analysis of a randomized three way cross over 
study of FVIII’s biological function suggests that hBFVIII is just as effective as full-length 
FVIII (72). These studies are conflicting and because of the very low levels of FVIII 
achieved in early clinical studies, the hBFVIII variant added very little progress to FVIII 
replacement gene therapy. In addition, hBFVIII appears to have the same propensity to 
lead to inhibitor formation in patients as full-length FVIII (22) and is therefore not the 
best treatment for hemophilia A. The incorporation of a Phe309Ser point mutation within 
the A1 domain of full-length FVIII facilitated a decrease in BiP binding to FVIII, and 
resulted in an increase efficiency of FVIII secretion (169). This secretory efficiency of 
hBFVIII was further increased 17-fold relative to hBFVIII by re-introducing 226 amino 
acids with 6 N-linked oligosaccharides of the B domain (N6) that was shown to be 
important for FVIII trafficking to the Golgi (102). However, only the N6 variant had 
long-term expression of FVIII activity and phenotypic correction in FVIIInull mice up to 
74 weeks, with low inhibitor titers (19).  
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Figure 1.4: Strategies for improving recombinant factor VIII (rFVII) (from 
Steve Pipe (131)). Increasing mRNA with BDD-FVIII. Increasing secretion of FVIII. 
Prolonging the half-life of FVIII by PEGylation and low-density lipoprotein related 
protein (LRP) mutations. Increasing the potency of FVIII by engineering IR8.  
 
  
 
18 
As mentioned in the previous section, FVIIIa forms an unstable heterotrimer that 
is susceptible to rapid dissociation of the A2 domain and proteolytic degradation by FIIa, 
FXa, and aPC. Thus another strategy to improve FVIII has been to increase its functional 
activity. The engineering of inactivation resistant FVIII (IR8), a B-domainless FVIII 
variant with the A2 domain fused to the light chain of FVIII, and missense mutations at 
the FIIa, FXa and aPC cleavage sites provides a FVIII single chain protein with maximal 
activity after a single cleavage at R372 (134). In vitro studies suggest that IR8 has a 5-fold 
higher specific activity than wild type (WT) FVIII. This same study showed that while 
WT FVIII is inactivated within 10 minutes of thrombin activation IR8 retains 38% of its 
peak activity even after 4 hours of activation. Nevertheless, the first in vivo study of IR8 
using a helper-dependent adenovirus for plasma expression in FVIIInull mice was 
disappointing, with activity levels reflecting that of WT FVIII. As the half-life of 
circulating FVIII is dependent on binding to vWF (124), the fact that IR8 does not bind 
vWF well (134) may be an explanation for this phenomenon. 
Other avenues of augmenting FVIII have been to prolong the half-life of FVIII by 
the conjugation of polyethylene glycol (PEG) polymers and polysialic acids (PSA) 
polymers, the stabilization of FVIII by binding PEG-modified liposomes (PEGLip), and 
the introduction of mutations within low-density lipoprotein receptor-related protein 
(LRP) to reduce FVIII clearance in vivo. The most common method used for PEGylation 
studies is the attachment of the PEG moiety to lysine residues and N-terminal amines 
within the native FVIII protein. However, these studies have confirmed that while 
prolonging the half-life through PEGylation can decrease the frequency of dosing FVIII 
not being able to control the site of PEGylation can also reduce the specific activity of 
FVIII (107), and affect the stability of FVIII in plasma due to a decrease interaction with 
vWF (148). In addition to this, PEGylation can also provoke an immunogenic response 
since PEGs are non-biodegradable (17). A recent study was successful in achieving site-
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specific PEGylation of hBFVIII.using site directed mutagenesis to introduce cysteine 
mutations on the surface of hBFVIII (99). This finding was associated with prolonged 
FVIII efficacy consistent with improved pharmacokinetics and vWF binding. PEGLip, 
PSA modification and receptor modified catabolism of FVIII takes care of some of the 
problems with PEG modification, and are very promising for promoting a longer acting 
FVIII; however, the overall effect of these modifications on the complex pharmacokinetic 
profile of FVIII in vivo is still unknown. 
 
 
1.3.2 Gene Therapy for Hemophilia 
Gene therapy is the introduction of a functional gene into a target cell to provide a 
therapeutic advantage (185). The overall goal of hemophilia gene therapy is to provide a 
long-term expression of FVIII or FIX (hemophilia B) without inducing host immunity to 
the transgene (45). In the case of hemophilia A, this would take care of the need for 
continuous intravenous injection of FVIII and improve the outcome of patient care. 
Hemophilia A has been identified as an ideal candidate for gene therapy for several 
reasons. First, it is a monogenic disease, therefore making it easy to manipulate cellular 
responses. Second, there are multiple organ targets available for FVIII expression, and 
therapeutic outcome can be monitored easily by detecting the plasma FVIII level (15) 
and following bleeding episodes. Third, theoretically there is a wide therapeutic window 
from >2% up to 150% for FVIII expression, and small increases in FVIII levels are 
sufficient to make a significant difference in disease phenotype. Additionally, the 
existence of small and large animals models of the disease also permits efficacy testing 
before getting to human subjects (56).  
 A number of studies have already been published in murine and canine models of 
hemophilia, and several clinical trials for hemophilia have advanced our understanding 
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of treating the disease (25, 192). Various cell types have been explored for hemophilia 
treatment, including hepatocytes, the muscle, EC and hematopoietic stem cells (HSC). 
Since the liver appears to be the main site of FVIII and FIX production, many 
hemophilia studies have employed hepatocytes as the target cell for replacement therapy 
(71, 100, 126). However, several of these animal studies observed that successful 
tolerance induction depended on the type of gene delivery vector, the transgene 
expression level, and a vector design that would avoid an immunogenic response against 
the transduced cells and transgene (37, 119). In muscle-directed studies, a boost in local 
immune response was associated with development of antibodies to the FVIII transgene 
(187). Additionally, since the delivery of plasma FVIII from muscle can be inefficient, 
possibly because of its size and because there are multiple proteases in the extracellular 
space of the muscle, muscle directed expression of FVIII is even more challenging than 
liver-specific expression. 
 Several clinical trials for hemophilia gene transfer studies in patients with 
Hemophlia A and B have been completed, with two other studies currently underway. 
The first Hemophilia A study began in 1998 and was conducted by Transkaryotic 
Therapies. This study employed an ex vivo/non-viral plasmid DNA approach to modify 
fibroblast from hemophilia A patients to express hBFVIII (149). Though no significant 
side effects were associated with this gene therapy approach, FVIII levels achieved were 
very modest in seven of the twelve patients enrolled. A second study conducted by 
Chiron directed hBFVIII gene expression to the liver using a replication-deficient onco-
retroviral vector derived from the Maloney murine leukemia virus (MLV) (142). This 
study showed safety of the MLV vector in patients, however like the fibroblast study, 
transient low rises in FVIII levels were seen in a few cases. The most recent Phase I 
hemophilia A clinical trial was a liver-directed expression study of full length FVIII based 
on the peripheral vein injection of a “gutted” adenovirus (20). FVIII levels achieved were 
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approximately 1%, and the first patient enrolled in this study was removed because he 
developed systemic side effects. Thus, there is still over avenues of research that have to 
be pursued in order to successful address FVIII replacement therapy.  
 As several studies have proposed that FVIII is naturally expressed in EC (52, 64), 
and two in vitro studies have shown that FVIII is expressed and stored in Weibel-Palade 
bodies along with its carrier protein vWF (146, 179), EC are an attractive target for FVIII 
therapy. A small number of studies have shown that one can phenotypically correct 
hemophilia A by directing FVIII expression to liver sinusoidal EC (78) and lung EC (87). 
However, in one study of EC-derived FVIII, this plasma FVIII was ineffective in 
improving hemostasis in the presence of FVIII inhibitors (162).  
 
 
1.3.2.1  FVIII Gene Transfer into Hematopoietic Stem Cells (HSC) 
HSC are an attractive target for gene therapy because they are self-renewal and can 
differentiate into multiple blood lineage cells. Moreover, they are easily obtained, can be 
efficiently cultured ex vivo with a gene therapy vector, and reinfused into patients (9, 
81). To date, most gene therapy studies into HSC are done using viral vectors, as these 
vectors are most efficient at transferring the transgene to recipient cells.  
 The first study to show that hemophilia A mice can be corrected by gene therapy 
was established using an onco-retroviral vector derived from the MLV. In this study, 
intravenous injection of FVIII resulted in a long-term expression of FVIII in newborn 
FVIIInull mice (180). In spite of this, a phase I clinical study using the same viral vector to 
treat severe Hemophilia A patients showed a low and transient rise in FVIII activity in 
patients (142). This has been attributed to the fact that these vectors are ineffective at 
transducing non-dividing stem cells (166). Presently, the vector generating the most 
interest for bone marrow gene therapy is the HIV-1 lentiviral vector. This viral vector can 
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integrate its proviral DNA into dividing and non-diving cells (2), and has a self-
inactivating (SIN) system built into the 3’ long-terminal repeat (3’LTR) that allows for 
transgene expression to be driven by the inserted tissue specific promoter. Immuno-
cytochemistry analysis of rat brains injected with a lentiviral vector expressing β-
galactosidase detected β-galactosidase positive neurons, oligodendrocytes, and 
astrocytes (111). A second study showed that this vector could efficiently induce 
transgene expression in vivo in non-quiescent hepatocytes (66) after local gene therapy. 
Of importance to this application, several groups (26, 106, 143, 167, 175) have utilized 
lentiviral vectors with ubiquitously acting promoters into HSC to correct hemophilia A. 
Some of these groups (26, 106, 143) have been successful at achieving plasma levels of 
FVIII that is sufficient to phenotypically correct the bleeding diathesis.  
 While the prospects of gene therapy are very promising, there are several 
difficulties associated with such therapy. First is that, despite obtaining long-term 
expression levels of FVIII in several animal models, overcoming the extremely low levels 
in human patients is still challenging (47). Second is that, it is necessary to avoid viral-
vector insertional mutagenesis and oncogene activation associated with using onco-
retroviral and lentiviral vectors when targeting HSC (112). Third, it is ideal to obtain 
successful stable transgene integration that does not elicit an immune response to the 
transgene. And finally, the strategy behind these studies correct plasma FVIII levels, and 
this may not be effective in patients already suffering with clinically relevant inhibitors.  
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1.3.2.2 Platelet-delivered Gene Therapy 
Since FVIII is structurally similar to FV, which is synthesized during megakaryopoiesis 
and stored in platelet α-granules along with its carrier protein multimerin (40). In 
earlier studies, Dr. Poncz had proposed that FVIII too can be synthesized in developing 
megakaryocytes and stored in α-granules along with its carrier protein vWF to be 
released specifically at sites of injury. In addition, to this a Phase I clinical study had 
already shown the feasibility of using patients’ fibroblast cells cultured and transfected 
ex vivo with hBFVIII to correct hemophilia A (142). Advantages to using this ectopic 
approach for FVIII expression is that: 1) storage in platelets would extend the half-life of 
FVIII in the circulation from the half-life of circulating plasma FVIII of ~10 hrs (172) to 
that of circulating platelets of ~10 days (94), 2) since platelets act at the immediate site 
of injury, platelet-derived FVIII (pFVIII) may be more effective in lower amounts than 
plasma FVIII, 3) platelets would provide a protective environment for FVIII and a 
decreased risk of being immunogenic, and 4) pFVIII may be protected from inhibitors 
and can treat patients with inhibitors.  
Our laboratory has been pursuing similar models of targeted platelet-delivered 
therapeutics to sites of vascular injury to enhance fibrinolysis and modulate hemostasis. 
To restrict transcription of the transgene to the platelet/megakaryocyte lineage, the 
transgene must be driven by a platelet lineage-specific promoter. We have been 
successful at developing anti-thrombotic thrombocytes that delivers urokinase-type 
plasminogen activator (uPA) to sites of vascular injury using a murine (m) PF4 platelet-
specific promoter (79). This uPA was expressed during megakaryopoiesis and stored in 
platelet α-granules. In another study using a platelet-specific GPIbα polypeptide (GPIbα) 
promoter we found that hBF8 was similarly expressed in platelets of FVIIInull transgenic 
mice Line no. 38 (phF8.38/FVIIInull), and released upon platelet activation (197). In this 
study, we confirmed that phBF8, even at a level of 3% normal plasma activity 
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equivalence, can correct the bleeding diathesis in FVIIInull mice in several injury models 
(197). This correction is platelet dependent, as transfusion of washed phF8.38/FVIIInull 
platelets into FVIIInull mice was able to correct hemostasis using a ferric chloride (FeCl3) 
carotid artery injury model. Since our initial publication on the efficacy of phBFVIII in 
FVIIInull mice, two other groups (123, 164, 165) have published similar studies, but 
achieved lower pFVIII levels using the αIIb promoter by transgenic and lentiviral 
approaches. Both groups had to rely on a very sensitive tail exsanguination model as a 
readout to show pFVIII hemostatic efficacy.  
As previous studies (69, 146) had suggested that co-expression of vWF and FVIII 
was needed for FVIII granular storage and secretion for an effective FVIII gene therapy, 
we tested the importance of vWF co-expression for ectopic storage of FVIII in platelet. 
We found that phBF8 can be stored in α-granules independent of vWF (pFVIII levels of 
~70% of that in vWF WT mice), and that the remaining pFVIII was biologically active 
following platelet activation (196). This was confirmed by another group (165); who also 
first demonstrated the effectiveness of pFVIII in the presence of circulating FVIII 
inhibitors (163, 165). However, this group reported that pFVIII was >106-fold more 
effective than infused FVIII. We studied this issue concurrently (41), but used the FeCl3 
carotid artery injury model and confirmed the efficacy of pFVIII in this setting, but that 
this benefit is more limited and is ~102-fold more efficacious than infused FVIII. 
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1.4 Motivation 
The general motivation behind this work is that since pFVIII would be released at sites of 
injury in a concentrated manner, inactivation of FVIII by antibodies can be limited, 
resulting in improved hemostasis in the presence of inhibitors. This gene therapy 
approach might be beneficial especially in treating hemophilia A patients with inhibitors.  
In our initial study of phBF8, we showed that the standard tail exsanguination 
model for correction of the murine hemophilia phenotype was too sensitive to study the 
efficacy of pFVIII, as many transgenic lines with undetectable hBFVIII message or 
protein survived the overnight injury. We believe that this model is an exsanguination or 
hypovolemic model that shunts blood away from the tail and allows platelets to release 
small levels of FVIII that can stop bleeding. Thus, we utilized the FeCl3 carotid artery 
injury and also a cuticular bleeding model, which is a combined arteriole/venule injury 
model of testing FVIII efficacy. We found that phBF8 was more effective than plasma 
FVIII in the carotid arterial injury, but less so in the cuticular mixed arterial/venule 
injury. Since increases in plasma FVIII levels appear to be associated with arterial and 
venule thromboembolism (85), we became concerned that pFVIII would be too 
efficacious after arterial injury which is mostly platelet-dependent. Using an in situ 
cremaster laser injury system, we showed that phBF8 improved clotting to the same 
extent on the arteriole and venule sides (116). However, these studies also showed that 
phF8.38/FVIIInull mice formed clots that were unstable than after a comparable plasma 
FVIII correction, leading to the search for a more effective platelet delivery strategy.  
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1.5 Problem Statement 
 The problems addressed in this work include the design and characterization of 
transgenic and bone marrow transplanted/lentiviral FVIIInull mice expressing FVIII 
variants with improved efficacy over hBF8 to improve pFVIII efficacy and reduce the 
embolization concern in FVIIInull mice. To address this challenge, several platelet specific 
promoters were compared to each other in a lentiviral model of gene therapy. After 
settling on a single promoter, variants of FVIII with increased specific activity relative to 
hBFVIII, IR8 and canine (c) B-domainless FVIII (cBFVIII) were compared in hemostatic 
models in FVIIInull mice. These studies lead in turn to a greater understanding of pFVIII 
during megakaryopoiesis and a novel hBFVIII variant, hBFVIIIR1645H, that appears to 
have important features for a clinical relevant FVIII for gene therapy. 
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Chapter 2 
High Specific Activity Factor VIII Variants, IR8 and cBF8 
 
 
2.1 Abstract 
Ectopically expressed, hBF8 in platelets improves hemostasis in hemophilia A mice in 
several injury models. However, in both a cuticular bleeding model and a cremaster laser 
arteriole/venule injury model, there were limitations to phBF8 efficacy, including 
unstable clot formation leading to increased clot embolization than after plasma FVIII 
correction. We now address whether variants of FVIII with enhanced activity, IR8 and 
cBF8, would improve clotting efficacy. In both transgenic and lentiviral murine model 
approaches, pIR8 expressed at comparable levels to phBF8, but pcBF8 expressed at only 
~30%. Both variants were more effective than hBF8 in cuticular bleeding and FeCl3 
carotid artery models. However, in the cremaster injury model, only pcBF8 was more 
effective, markedly decreasing clot embolization. Since inhibitors of FVIII are stored in 
platelet granules and IR8 is not protected by binding to Von Willebrand factor, we also 
tested whether pIR8 was effective in the face of inhibitors and found that pIR8 is 
protected from the inhibitors. This observation may be important when we begin 
FVIIInull canine studies as dogs lack vWF in their platelets. In summary, pFVIII variants 
with high specific activity are more effective in controlling bleeding, but this improved 
efficacy was inconsistent for different FVIII in the various bleeding models, perhaps 
reflecting the underlying mechanism(s) for the increased specific activity of the studied 
FVIII variants.  
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2.2 Background 
Gene therapy for FVIII replacement is attractive as there is a wide therapeutic window 
for FVIII corrective plasma levels (39). Past gene transfer studies have focused on liver 
expression of hFVIII; and have proven to be a successful strategy for FVIII replacement 
therapy, however, sustained high FVIII expression levels are difficult to achieve (75, 106, 
175). One approach to improve outcome in these studies has been to increase the efficacy 
of the FVIII by designing variants of FVIII with improved in vitro activity (134). IR8 is 
one such variant and has increased resistance to FIIa, FXa and aPC inactivation in vitro 
(133). However, this variant also has a decreased vWF binding, which may limit its 
plasma half-life and clinical utility (19). 
Previous work has demonstrated that targeted delivery of ectopic hBFVIII from 
within platelet α-granules is effective at improving clotting in phBF8/FVIIInull mice (164, 
197). Most importantly, phBFVIII remains markedly more effective in the presence of 
circulating inhibitors than plasma hBFVIII (41, 163, 165). This pFVIII is also stored in α-
granules independent of vWF and can be effective when released at sites of injury in 
FVIIInull mice (164, 196). Despite having this advantage, we found that the efficacy of 
phBFVIII in FVIIInull mice varied based on the bleeding model studied. In particular, 
phBFVIII was not as effective in the arteriole/venule cuticular bleeding model (197). Of 
greater concern was that phBFVIII was associated with increased arteriole and venule 
embolization in the cremaster injury model. This is likely due to the observation that α-
granule release begins in the base of a growing clot and then extends throughout the clot, 
perhaps leading to inadequate fibrin generation at key areas within the clot (116).  
Thus, while pFVIII appears to be an attractive strategy for hemophilia A therapy 
because of its potential use in the setting of inhibitors, one also needs to carefully 
examine whether this ectopic expression delivery system would not lead to untoward clot 
embolization. In this study, we tested whether using two FVIII variants with increased 
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FVIII activity, the above-mentioned IR8 and cBFVIII the latter, a species of FVIII that 
has 3-5-fold greater specific activity than hBFVIII (152, 158) could decrease clot 
instability.  
 
 
2.3 Materials and Methods Used 
2.3.1 pFVIII Transgenic Mice Constructs and Characterization 
cDNAs for IR8 (134) and cBFVIII (157) were kindly provided by Drs. Rita Sarkar and 
Haig Kazazian, at the University of Pennsylvania, with Not I restriction sites immediately 
upstream and downstream of the coding sequence. The cDNAs were sub-cloned into a 
similarly prepared, previously described (38) vector, encoding the murine 
megakaryocyte specific GPIbα (2.6 kb) proximal promoter region plus a 5’ untranslated 
region (UTR) 1st exon and part of its 1st intron with Xho I restriction sites at both ends, 
replacing hBFVIII, as shown in Figure 2.1. The constructs were used to create transgenic 
mice by pronuclear injections as described (197). Genomic DNA was isolated from 
mouse-tails using direct polymerase chain reaction (PCR) Lysis reagent (Viagen Biotech 
Inc., Los Angeles, CA) and positive transgenic lines were defined using genomic PCR 
amplification as previously described (197). Murine studies were done with Institutional 
Animal Utilization Committee approval.  
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Figure 2.1 Expression vector maps. pBSK-derived vector used in the transgenic 
expression studies contained the immediate proximal promoter of the murine GPIbα 
gene (green bar), its first 5’-untranslated region (UTR) exon (green box) and the 
beginning of its first intron (thin line) completed with an SV40 splice acceptor/5’UTR 
(thin line and blue bar) (38). This is followed by the FVIII cDNA (red box) with 
translation indicated by the bent arrow. The 3’UTR is derived from SV40 (green bar) and 
contains a polyadenylation sequence (38) Important restriction sites used in the 
construction were N = Not I, S = Sal I, and X = Xho I. (B) SIN lentiviral construction 
based on the human immunodeficiency virus type 1 (HIV-1) (105) used to express FVIII 
either using the widely expressed 1.2 kb ubiquitin or 1.1 kb murine PF4 proximal 
promoters (green bar, (79, 111)). LTRs are indicated as closed boxes with the SIN 
element in the 3’UTR as an open insert. Ψ = packaging signal, ppt = HIV-1 flap element 
for insertional stability (polypurine tract), and WRE = Woodchuck hepatitis virus post-
transcriptional regulatory element. The FVIII cDNA insert is shown as a red box with 
translation indicated by the bent arrow. Relevant restriction sites include B = BamH I, P 
= Pac I, S = Sal I, and X= Xho I. 
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Positive founder lines were tested for ectopic FVIII message in platelets as 
described (197). Platelet-rich plasma (PRP) was obtained from 1 ml of murine inferior 
vena cava blood anticoagulated with acid citrate dextrose (ACD; pH 4.5, 10:1 vol/vol). 
The platelets were then pelleted at 600g for 10 min, then homogenized and total platelet 
mRNA was isolated using RNA STAT-60 (Tel-Test Inc., Friendswood, TX). Reverse 
transcription (RT) was performed using the SuperScript II Reverse Transcriptase Kit 
(Life Technologies, Bethesda, MD) as per the manufacturer’s instructions. RT-PCR 
amplification was done using a GPIbα exon 1 (5’-TCTGTTCCTCCAAAGGACTG-3’) sense 
primer and a hBFVIII coding region (5’-CACAGGCAGCTCACCGAGATC-3’) antisense 
primer, yielding a 320-bp cDNA fragment for IR8. For cBFVIII transgenic message, the 
antisense primer (5’-CAGCACCTTCAGAAGCTTTC-3’) was used instead to detect a 600-
bp cDNA fragment. Platelet specific control RT-PCR primers for mouse PF4 message 
were sense 5’-GTAGAACTTTATCTTTGGGT-3’ and antisense 5’-
AATTTTCCTCCCATTCTTCA-3’, with an expected size of 300-bp illustrated in Figure 
2.2. 
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Figure 2.2: FVIII message level in transgenic mice platelets. Representative 
study of 3 studies. Shown is an ethidium bromide 1% agarose size-fractionation gel of the 
RT-PCR amplification products for pFVIII (lanes 1 and 2) and PF4 (lanes 4 and 5), 
representing two separate platelet RNA aliquots. Lane 3 = tail genomic DNA PCR from 
the mice. Transgene involved are indicated at the top. phBF8 is transgenic Line hF8.38, 
for pIR8 is transgenic Line IR.5 and for pcBF8 is transgenic Line cF8.24. Marker is Phi-
X Hae III.  
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Transgenic lines expressing different levels of pFVIII were crossed onto the 
previously described (10) FVIIInull mice background (provided by Dr. Kazazian), which 
has a targeted disruption of exon 16. Genomic confirmation was done using PCR 
amplification, primer pairs for mouse GPIbα promoter region 5’-
ATGCAGACTAGAATGTCAGC-3’ sense primer and an SV40 region 5’-
ACCAGTTAACTTTCTGGTTTTTC-3’ antisense primer, which generates a 600-bp 
genomic band for phFVIII and pIR8, and a 800-bp band for pcBFVIII (Figure 2.2) 
following amplification conditions previously described (10). For most studies, FVIIInull 
male mice that were transgenic for the pFVIII constructs were compared to sibling male 
FVIIInull mice that were pFVIII non-transgenic.  
 
2.3.2 Lentivirus Vector Construction and Correction of FVIIInull Mice 
The FUGW SIN lentivirus was based on HIV-1 and has been previously described (105). 
This vector has a ubiquitin promoter driving eukaryotic green fluorescent protein (eGFP) 
expression (89). For megakaryocyte eGFP expression studies, we replaced the 1.2 kb 
ubiquitin promoter with 1.1 kb of the mPF4 promoter, 0.9 kb of the hαIIb promoter, and 
2.6 kb of the GPIbα promoter. For FVIII expression studies, we replaced the ubiquitin 
promoter with the PF4 promoter (79), and the eGFP was replaced with FVIII cDNAs for 
hBF8, IR8 and cBF8 as highlighted in Figure 2.1B using the restriction sites noted. 
Infectious stocks of vectors were produced by transient transfection of human embryonic 
kidney (HEK) 293T cells as illustrated in Figure 2.3, by Ca3(PO4)2 precipitation as 
described (89) with three plasmids: the appropriate lentiviral plasmid as shown in Table 
2.1, the cytomegalovirus ∆8.2 (CMV∆8.2) packaging vector, and the vesicular stomatitis 
virus glycoprotein (VSVG) envelope vector (111). Transfections were performed with 11 
μg/ml of plasmid DNA, 7 μg/ml CMV∆8.2, and 3.9 μg/ml of VSVG in Dulbecco’s 
modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 1% 
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of penicillin and streptomycin (PS) and 1% L-glutamine (LG) (all GIBCO BRL, Carisbad, 
CA). Viral supernatant was collected 48 hrs post-transfection, and concentrated by 
ultracentrifugation at 30,000g for 2 hrs. Viral pellets were resuspended in DMEM and 
stored at -80°C until used. Viral titers were quantified for both infectivity (transforming 
units (TFU)/ml), and total RNA content. For TFU/ml, 3T3 fibroblast cells were infected 
with serial 10-fold dilutions of the lentiviral supernatant. The percent positive cells for 
eGFP were determined by flow cytometry. For hBF8 viral stocks, viral infectivity was 
determined using a sheep polyclonal anti-hFVIII fluorescein isothiocyanate (FITC)-
labeled antibody (Affinity Biologicals, Westchester, OH) by flow cytometry after 
intracellular fixation and permeabilization. For total RNA content, virus particle (VP)/ml 
was measured using a quick-titer lentiviral kit (Cell Biolabs, Inc., San Diego, CA) for 
hBF8 and cBF8. 
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Table 2.1: Lentiviral constructs. Promoter and transgene used to make 
constructs. P = 1.1 kb of mouse murine PF4 proximal promoter (79), α= 0.9 kb of 
hαIIb proximal promoter , and G= 2.6 kb of the proximal GPIbα promoter (197). 
Transgenes are G = eukaryotic green fluorescence protein, hF8 = hBFVIII, IR8, 
and cF8 = cBFVIII.  
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Figure 2.3: Schematic representation for virus production in HEK 293T 
cells. The 3-plasmid lentiviral components: the packaging vector Δ8.2, the lentiviral 
plasmid DNA, and the envelope vector VSVG were transiently transfected in to 293T 
cells by Ca3(PO4)2 precipitation. Two days post transfection virus was collected from the 
media and concentrated by ultracentrifugation.  
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These lentiviral stocks were used to transfect murine marrow as shown in Figure 
2.4. Whole bone marrow was collected from femurs and tibias of donor FVIIInull mice 
and cultured for 48 hrs at 37°C in 5% CO2 in DMEM containing 15% FBS, 1.25% PS, 
1.25% LG, 6 ng/ml of recombinant murine (rm) interleukin (IL)-3, 10 ng/ml rmIL-6, and 
100 ng/ml of rm stem cell factor (rmSCF) (all Pepro-Tech Inc., Rocky Hill, NJ). Cells 
were transduced at 5-10 x 106 cells per well of a 24-well non-tissue culture-treated plate 
(Falcon-Becton Dickinson, Franklin Lakes, NJ) coated with 10-20 μg/cm2 of Retronectin 
(PanVera, Madison, WI) by spin infection at 2000g for 1.5 hrs. Multiplicity of infection 
was optimized for each lentiviral stock by in vitro marrow transduction and growth of 
megakaryocytes as described (164). 
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Figure 2.4: Schematic representation for bone marrow transplantation 
studies. FVIIInull bone marrow was extracted and cultured with cytokines as described 
in the text for up to two days. These bone marrow cells were then transfected with FVIII 
virus and injected into hαIIb/FVIIInull mice.  
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On the day of bone marrow transplantation (BMT), 6-to-8 week old recipient 
FVIIInull mice expressing only human αIIb/mouse β3 on their platelets (to distinguish 
donor vs. recipient platelets) (174) received a lethal dose of 1000 cGy of total body 
irradiation in a split dose. Three hrs post irradiation, 2-5 x 106 virally transduced BM 
cells in a volume of 150-200 µl of phosphate-buffered saline (PBS) was injected via the 
tail vein. Platelet count recovery was monitored starting at 3-weeks post transplantation, 
and the degree of chimerism was determined by flow cytometry using a phycoerythrin 
(PE) conjugated rat anti-mouse αIIb (CD41) antibody (BD Pharmingen, Franklin Lakes, 
NJ) and a FITC-conjugated anti-human αIIb antibody (eBioscience, San Diego, CA).  
 
2.3.3 Determination of eGFP Expression 
Transfection studies have shown that FUGW can efficiently infect and be expressed in 
hematopoietic tissue (89). Lentiviral constructs were made by substituting platelet-
specific promoters for the ubiquitin promoter into the Pac I/Bam HI site shown in 
Figure 2.1. The mPF4 promoter was effective at driving urokinase expression in 
megakaryocytes of transgenic mice (79). The platelet-specific specific GPIbα promoter 
induced ectopic platelet expression of FVIII and storage within platelets α-granules 
(197), and its expression in transgenic mice was also effective at alleviating murine 
Bernard–Soulier Syndrome (189). The hαIIb promoter, originally generated and studied 
by Dr. Poncz (173), is homologous to the mαIIb, and has been used successful at 
correcting Glanzmann thrombasthenia in a murine model by a lentiviral strategy (194). 
Whole bone marrow cells were transduced with eGFP expressing lentivirus shown in 
Table 2.1. Two days post transduction, the number of megakaryocytes expressing eGFP 
was determined by flow cytometry by staining the cells with 1 µl of PE-conjugated rat 
anti-mouse CD41.  
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2.3.4 Determination of FVIII Antigenic and Functional Levels 
Levels of hBFVIII and IR8 in plasma and platelets of both transgenic and bone marrow 
reconstituted mice were determined using an anti-human specific enzyme linked 
immunosorbent assay (ELISA) kit (Affinity Biologicals) compared to recombinant full-
length hFVIII protein (Baxter Health Corporation, Westlake Village, CA). cBFVIII levels 
were detected using a cFVIII-specific ELISA as described (152) compared to purified 
recombinant cBFVIII protein (and using reagents kindly provided by Dr. Valder Arruda, 
the University of Pennsylvania) (152). Platelets rich plasma (PRP) was prepared as 
previously described (197), and platelets were pelleted at 600g for 10 mins and 
resuspended in Tyrode’s buffer (139 mM NaCl, 2.9 mM KCl, 0.34 mM NaHPO4, 12 mM 
NaHCO3, 20 mM HEPES, 1 mM MgCl2, pH 7.28). Total pFVIII determinations were 
done using platelet lysate after 3 cycles of freeze/thaw at -80°C/37°C of the platelet 
pellet. For platelet-releasate FVIII determination, platelets were incubated at 37°C with 
thrombin (final concentration, 1U/ml) (Sigma Aldrich, St. Louis, MO) for 10 mins. Both 
total and releasate samples were then centrifuged at 600g for 15 mins, and the 
supernatant frozen at -80°C until assayed for FVIII antigen. To obtain platelet poor 
plasma, (PPP) prostaglandin E1 (final concentration, 1 µM) was added to 1 ml of PRP 
prior to pelleting the platelets. The PPP was frozen at -80°C until assayed for FVIII 
antigen. Platelet lysate/releasate and plasma levels from FVIIInull and WT mice were 
simultaneously measured.  
For transgenic mice, functional levels of FVIII was determined by two 
approaches: a two stage clotting Coatest assay using a Coamatic Factor VIII kit and a 
thrombin generation assay (TGA) (both DiaPharma Group, Franklin, OH) both as 
described by the manufacturer. The two-stage Coatest assay was done after activation of 
platelets with phorbol 12-myristate 13-acetate (PMA) (final concentration, 500 nM) for 
15 minutes at 37°C. Thrombin generation studies were done using crude PRP. Full-
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length recombinant hFVIII protein and normal pooled canine plasma (152) were used as 
standards for the quantification of FVIII activity. Controls were PRP from FVIIInull and 
WT mice. 
 
2.3.5 Cuticular Blood Loss Studies 
Cuticular bleeding time study was done using the middle hind digit of 6-to-10 week old 
mice as described (197). Before the removal of the cuticle, blood was collected by retro-
orbital puncture to determine initial hemoglobin levels. Each animal was then placed 
into a cage onto a sheet of filter paper (2M, Whatman International, Maidstone, 
England). The filter paper was replaced hourly, and the time to the first dry sheet was 
recorded. At the end of 6 hrs, another blood count was determined prior to euthanizing 
the animal.  
 
2.3.6 FeCl3 Carotid Artery Studies 
For transgenic mice studies, FeCl3-induced carotid arterial injuries were performed 
following a standard model as previously described (35, 79, 197) using 6-to-8 week old 
animals. Briefly, the right common carotid artery was exposed by blunt dissection, and a 
miniature Doppler flow probe (Model 0.5VB; Transonic Systems) was positioned around 
the artery. A 1 x 2 mm2 strip of 1M Whatman filter paper soaked in 10%, 15% or 20% 
FeCl3, was applied to the advential surface of the artery for 2 mins. The area was then 
flushed with PBS, and blood flow through the artery was continuously monitored for 30 
mins. The presence or absence of arterial occlusion (average blood flow) was recorded. 
For BMT/lentiviral (BMT/Lenti) studies, since FVIII antigenic levels and platelet counts 
were lower than the transgenic mice, arterial injury was induced with 20% FeCl3 for 4 
mins.  
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2.3.7 Cremaster Laser Injury Thrombus and Embolization Studies 
pFVIII/FVIIInull transgenic mice were intraperitoneally injected with sodium 
pentobarbital (11 mg/kg, Abbott Laboratories, North Chicago, IL), and maintained under 
anesthesia with the same anesthetic delivered via catheterized jugular vein as described 
previously (18, 30, 116). Rat anti-mouse CD41 antibody (Clone MWReg30) was 
purchased from BD Pharmingen and Fab fragments were produced using the 
ImmunoPure Fab Preparation kit (Pierce Biotechnologies, Rockford, IL) and conjugated 
with Alexa488 using an Alexa Fluor Protein labeling kit (Molecular Probes, Eugene, OR). 
For the embolization studies, a separate batch of anti-CD41 Fab fragments was similarly 
labeled with Alexa647. A murine anti-human fibrin antibody, which was shown to cross 
react with murine fibrin (61), was kindly provided by Dr. Hartmut Weiler from the 
University of Wisconsin and was also conjugated with Alexa647. The cremaster muscle 
was isolated and the microvessels studied using an Olympus BX61WI microscope 
(Olympus Tokyo, Japan or Center Valley, PA) with a 40X/0.8 numeric aperture (NA) 
water-immersion objective lens. Labeled antibodies for platelets and fibrin were injected 
intravenously into the jugular vein 5 mins before injury and laser injury was induced 
using an SRS NL100 Nitrogen Laser system (Photonic Instruments, St. Charles, IL) at 
65% energy level with blood vessels ranging in sized from 20 to 40 µm. Data was 
collected at 5 frames/sec (f/s) over a course of 2.5 mins for all studies except 5 mins for 
phF8.38/IR8.5 comparative studies. No more than five arteriole and five venule injuries 
were done per mouse. In embolization studies, the use of multiple channels was omitted 
to increase the rate of image acquisition to ~62.5 f/s collected over 4 mins in a 
downstream mask as previously described (116). Number and size of platelet emboli was 
collected. Each film was manually reviewed to be assured that only studies with free-
flowing emboli were included in the final analysis. All data were analyzed using 
Slidebook software version 5.0 (Intelligent Imaging Innovations, Denver, CO).  
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2.3.8 IR8 Inhibition Studies 
Mice that were either phF8.38/FVIIInull and pIR8.5/FVIIInull were studied in the FeCl3 
carotid artery injury model in a FVIII inhibitor model previously described (41). These 
mice were given either 1.5 µg, 3.0 µg or 7.5 µg total of a 1:5 (µg/µg) inhibitor cocktail of 
monoclonal antibodies ESH8:GMA-8021 in 100 µl of PBS (American Diagnostica, 
Stamford, CT and Green Mountain Antibodies, Burlington, VT, respectively) (41) on days 
0, 3, 6, and 9 by retro-orbital injection. A control group was given control murine isotype 
immunoglobulin (Ig)G (Innovative Research, Novi, MI) in the same amounts over the 
same 9-day schedule. In a separate chronic study, mice were given 1.0 µg or 5.0 µg total 
of purified IgG from FVIII deficient plasma with inhibitors purchased from George King 
Biomedical Inc. In acute studies, separate hF8.38 and IR8.5 transgenic FVIIInull mice 
were given a single dose of 7.5 µg total of the inhibitor mix on day 10. All injury studies 
were performed on day 10 with 15% FeCl3 for 2 minutes, and blood flow was measured 
for 30 mins.  
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2.4 Results 
To begin to address a vector-based approach of pFVIII gene therapy for hemophilia A, 
we tested several megakaryocyte-specific lentiviral constructs for maximal tissue-specific 
eGFP expression in developing murine megakaryocytes. Ex vivo and follow up in vivo 
studies revealed high expression levels of eGFP in megakaryocytes and platelets 
following FPGW infection of whole marrow. 
To address the issue of the increased risk of unstable clot formation using platelet 
delivery of FVIII in a FVIIInull mice setting, we proposed to study the effect of ectopically 
expressing two FVIII variants with increased FVIII specific activity IR8 and cBFVIII. We 
found that both FVIII species were stored in murine platelets and released upon platelet 
activation. While pIR8 antigen reached levels comparable to phBF8, surprisingly pcBF8 
was expressed at ~30% of the level of phBF8 using both transgenic and lentiviral 
expression approaches. Both of these FVIIIs were more effective than phBF8 in the FeCl3 
and cuticular model; however, only pcBF8 was more effective than phBF8 and pIR8 in 
the cremaster model. This improved efficacy by pcBF8 was associated with a marked 
decrease in embolization rate to almost that in WT mice. Additional observations on the 
efficacy of pFVIII in the FVIIInull mice were also made with regard to the benefit of 
concurrent low-level plasma FVIII on pFVIII efficacy, and on the importance of vWF 
binding of FVIII on the protection of pFVIII from circulating inhibitors. We found that 
the concurrent low-expression of plasma FVIII was not better than the expression of 
pFVIII alone, and that IR8 remains effective in the presence of FVIII inhibitors.  
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2.4.1 eGFP Expression in Megakaryocytes and Platelets  
Ex vivo transduction of eGFP into whole bone marrow cells resulted in high expression 
levels of eGFP in both megakaryocytes and other lineages following FUGW infection, 
with this being the only lentiviral construct that had eGFP expression in the right lower 
quadrant as shown in Figure 2.5. The strongest megakaryocyte-specific expression of 
eGFP was seen with FPGW, ~35% megakaryocytes compared to 10% for FαGW, and 
background levels for FGGW as shown in Figure 2.5.  
We pursued in vivo BMT/Lenti studies using the FUGW and FPGW constructs as 
these two constructs showed the most promise in our initial in vitro studies. We found 
that a significant portion of platelets were eGFP positive using both constructs. However, 
the mPF4 promoter resulted in a more favorable eGFP expression, ~8 fold higher than 
the ubiquitin promoter as shown in Figure 2.6. This finding and our in vitro studies 
suggested that the ideal promoter to study platelet delivery of ectopic proteins is the 
mPF4 promoter. For this reason our pFVIII lentiviral studies were carried out using the 
ubiquitin promoter for maximal ubiquitous expression in HSCs and the mPF4 promoter 
for maximal platelet-specific expression. 
 
  
 
46 
 
 
Figure 2.5: Lentiviral delivery of eGFP expression into total murine bone 
marrow: ex vivo studies. Flow cytometry analysis of bone marrow cells focusing on 
large, αIIb+ megakaryocytes. Negative control is untransduced cells. Lentiviral vectors 
used are described in Table 2.1.  
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Figure 2.6: Flow cytometric analysis of post-BMT/Lenti mice. Shown are eGFP 
levels gated for platelet size. (A) Platelets from FUGW study. (B) Platelets from the 
platelet specific mPF4 promoter lentiviral study. 
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2.4.2 pFVIII Antigenic and Activity Levels in Transgenic and Post-
BMT/Lenti FVIIInull Mice 
A series of pIR8 and pcBF8 transgenic mice lines were established. Those with 
detectable pFVIII message levels were crossed onto a FVIIInull background. These 
pFVIII/FVIIInull lines were then compared to the previously described phBF8/FVIIInull 
line (phF8.38), wherein the highest level of releasable hBFVIII was noted (197). For 
pIR8/FVIIInull lines, FVIII antigen was measured in platelet-lysate and releasate and in 
parallel plasma samples using an anti-hFVIII ELISA as shown in Figure 2.7A. Similar 
studies were done as illustrated in Figure 2.7B for pcBFVIII using a similarly designed 
anti-cBFVIII ELISA.  
The selected transgenic line had very different antigen levels of pFVIII for both 
pIR8 and pcBFVIII and thus allowed us to study the efficacy of these variants over a 
range of pFVIII levels. The highest expression pIR8 line had releasable pIR8 level that 
was >70% of that seen with the highest expressing phBF8 line phF8.38 (Figure 2.7A), 
consistent with our previous finding that the lack of vWF binding only minimally 
decreases pFVIII storage (196). Based on the efficient expression of cBFVIII expression 
in baby hamster kidney (BHK) cells as compared to hBFVIII (152), we expected that 
cBFVIII would be highly expressed in murine megakaryocytes. Surprisingly, maximum 
pcBFVIII antigenic levels achieved by a transgenic approach was only ~30% of that seen 
with phBFVIII (Figure 2.7B). 
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Figure 2.7: FVIII levels in pFVIII transgenic mice. (A-B) Antigenic levels in 
platelet lysates (red bars), and releasates (red striped bars), and plasma (blue bars) were 
measured. (A) shows the transgenic pIR8 studies and (B) the pcBF8. The highest 
expressing phBF8 line previously studied phF8.38 (197) is included as positive control. 
All mice were FVIIInull. Background measurements in FVIIInull mice were subtracted from 
expressed FVIII levels. Mean ± 1 standard deviation (SD) are shown. The numbers of 
animals studied in each arm are shown above each bar.  
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 Because expression levels and tissue distribution in transgenic lines can vary 
widely depending on copy number and genomic site of insertion, a second approach was 
also carried out to examine the ability to express phBFVIII, pIR8 and pcBFVIII. These 
studies were done using a BMT/Lenti approach where viral constructs had identical 
promoters and anticipated levels more likely would depend on the FVIII being 
expressed. Lentiviral studies supported the transgenic line studies, suggesting that pIR8 
antigenic levels are comparable to that of phBFVIII (Figure. 2.8A), and pcBFVIII was 
only ~30% antigenic level of that seen with phBFVIII (Figure 2.8B). 
Some of our pIR8 (IR8.16 and IR8.18) and pcBF8 (cF8.30 and cF8.41) transgenic 
lines had detectable plasma FVIII as well shown in Figures 2.7A-B, an observation that 
was not seen in our prior studies with phBF8 transgenic lines (197). This is unlikely due 
to pIR8 or cBFVIII “leaking”. The GPIbα promoter used in the transgenic studies may 
normally also be active at a low level in EC (195) and/or random genomic insertion may 
have lead to FVIII expression in EC or other marrow cells, and ultimately its presence in 
the plasma. Additionally, lentiviral studies with the ubiquitin promoter also showed the 
presence of plasma IR8 and cBFVIII (Figures 2.8A and 2.8B, respectively), but with the 
megakaryocyte-specific mPF4 promoter, this did not occur even though the pFVIII levels 
were higher. Our observations with the ubiquitin-driven lentivirus of detectable plasma 
FVIII are consistent with other studies using ubiquitously expressing lentiviruses, where 
plasma FVIII was seen in similar BMT/Lenti FVIII studies (26, 143). 
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Figure 2.8: FVIII levels in post-BMT/Lenti FVIIInull mice. (A-B) Antigenic levels 
in platelet lysates (red bars), and releasates (red striped bars), and plasma (blue bars) 
were measured in these FVIIInull mice post-BMT. (A) Shows BMT/Lenti hBF8 and IR8 
studies. (B) Shows cBF8 studies. U = studies with the lentivirus driven by the ubiquitin 
promoter and P = studies with the mPF4 promoter. BMT38 were FVIIInull mice 
reconstituted with marrow from the phF8.38 transgenic. All mice were FVIIInull. 
Background measurements in FVIIInull mice were subtracted from expressed FVIII 
levels. Mean ± 1 SD are shown. The numbers of animals studied in each arm are shown 
above each bar.  
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FVIII activity was determined in the highest expressing pFVIII transgenic lines 
for pIR8/FVIIInull (pIR8.5) and pcBF8/FVIIInull (pcF8.24) and compared to phF8.38 in 
platelet releasate and in plasma as shown in Figure 2.9A. Our studies suggest that pIR8.5 
platelet releasate had an ~1.5-fold increased activity over phF8.38 platelet releasate, 
consistent with prior studies that reported increased specific activity of IR8 relative to 
hFVIII (19, 134) and the near-equal antigenic level of pIR8 in the platelets (Figure. 2.7A). 
For pcF8.24, a 1.7-fold increase over line phF8.38 is also consistent with published 
studies on the specific activity of cBFVIII relative to hBFVIII (152, 158) and the 70% less 
antigenic level in platelets (Figure 2.7B). In all three of these transgenic lines on a 
FVIIInull background, plasma FVIII activity levels were undetectable, consistent with the 
antigenic studies. Thrombin generation studies were also done using PRP in these 
pFVIII transgenic lines as another measure of FVIII activity. We found that the time-
dependent changes in thrombin concentration for pIR8.5 and pcF8.24 relative to 
phF8.38 corresponded to the fold change in increased activity of 1.5 and 1.7, respectively 
as shown in Figure 2.9B.  
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Figure 2.9: FVIII activity levels in highest pFVIII transgenic mice. (A) 
Chromogenic Test from platelet releasate (red stripe bars) and plasma (blue bars). (B) 
Thrombin generation (TGA) studies of FVIII activity from platelet releasate (red bars). Mean 
± 1 SD are shown. The numbers of animals studied in each arm are shown above each bar.  
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2.4.2 Cuticular Bleeding Studies 
We have previously shown that the standard tail bleed model, which involves both 
arteriole and venule injuries, requires very low levels of pFVIII to be fully corrective (48, 
197). Our initial studies with the standard tail bleed model suggested that it was too 
sensitive of a model to test pFVIII efficacy, as several of our transgenic lines that had 
undetectable hBFVIII cDNA clotted in this model. We therefore developed a cuticular 
bleed model that also involves arterial and venule injury, but is less sensitive to low 
pFVIII levels. The time to cessation of bleeding varied among the pFVIII/FVIIInull 
transgenic mice: pIR8.5 and pcF8.24 had shorter times than phF8.38 as shown in Table 
2.2, p < 0.03 relative to phF8.38. The percent drop in hemoglobin was the same in WT 
and all the pFVIII transgenic/FVIIInull mice (p > 0.52), showing good hemostatic efficacy 
of all three pFVIII’s in this model. In lentiviral studies there was no difference in the time 
to cessation for all of the ubiquitin and mPF4 promoter-driven variants as shown in 
Table 2.3 ( p >. However, mice expressing the mPF4-driven FVIII variants had less blood 
loss than the ubiquitin promoter-driven mice. The lentiviral approach had lower platelet 
counts than the transgenic mice (520 ± 85 x 109 vs. 1120 ± 140 109 per liter of blood, p < 
0.015), and the level of pFVIII antigen was roughly half (compare Figures 2.7 and 2.8). 
The combination of the two may explain why the BMT/Lenti-reconstituted FVIIInull mice 
expressing pFVIII were not as hemostatically efficient as the best transgenic lines. 
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Table 2.2: Cuticular bleeding time in pFVIII transgenic mice. Clotting time in 
hours and the percent of original hemoglobin at the end of the 6-hour study. Values are 
shown as means ± 1 SD. * = p < 0.03 relative to phF8.38. 
 
 
 
Table 2.3: Cuticular bleeding time in FVIII BMT/Lenti mice. Clotting time in 
hours and the percent of original hemoglobin at the end of the 6-hour study. Values are 
shown as means ± 1 SD. * = p < 0.04 relative to FVIIInull. 
 
 
  
 
56 
2.4.3. FeCl3 Carotid Artery Injury Studies 
Previously, we showed that clotting in the FeCl3 carotid artery injury model followed a 
dose-response to infused hFVIII (197). In that study, we showed that phF8.38/FVIIInull 
was effective at clotting after a standard 2 minute 20% FeCl3 injury, but that other 
phBF8/FVIIInull lines with lower pFVIII levels did not develop occlusive clots (197). 
Therefore, we tested the degree of correction of the various transgenic pIR8 and pcBF8 
lines on the FVIIInull background in this system compared to phF8.38/FVIIInull mice as 
positive control and FVIIInull mice as negative control. Despite having lower pFVIII levels 
than line phF8.38, virtually all of the lines exhibited normal clotting after a standard 
20% FeCl3 injury as shown in Figures 2.10A-B, top panel. We therefore used less 
chemosclerotic injuries, and showed that pIR8 and pcBF8 were more effective than 
phF8.38/FVIIInull mice after these milder injuries illustrated in Figures 2.10A-B, middle 
and bottom panels. Moreover, line IR8.18/FVIIInull, which expresses both plasma and 
pIR8, was no more effective than IR8.16/FVIIInull line that expresses pIR8 at an 
equivalent level, but with no concurrent plasma FVIII, suggesting that there is no 
synergistic effect of having both platelet and low circulating plasma FVIII in this model. 
The highest plasma FVIII antigenic level observed in these studies is equivalent to 10% 
plasma FVIII correction. We do expect that if the plasma FVIII levels in our transgenic 
mice were to go above 12% FVIII correction then we will begin to see an effect of having 
concurrent platelet and plasma FVIII levels. However, for the ectopic platelet-delivery 
model we proposed in our studies, we are not interested in having concurrent plasma 
FVIII levels.  
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Figure 2.10: Transgenic FeCl3 carotid artery studies. Transgenic lines for pIR8 
(A) and pcBF8 (B) were studied for clot development in the carotid artery injured with 
20%, 15% and 10% FeCl3 for 2 mins (left to right). Mean ± 1 SD of blood flow rate seen 
over 30 mins are shown for the various transgenic lines (defined on the right) 
represented at their mean pFVIII antigenic levels in Figures 2.6A and 2.6B. Grey 
horizontal bars = the mean ± 1 SD for blood flow rate in WT (lower horizontal bar) and 
FVIIInull (upper horizontal bar) mice. N > 5 mice per arm. * = p <0.035 relative to 
phF8.38.  
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These two findings are further supported in FeCl3 injury studies using FVIIInull 
mice reconstituted with FVIIInull marrow transduced with ubiquitin- or mPF4-promoter 
driven phBFVIII, pIR8 or pcBFVIII lentiviral constructs shown in Figure 2.11A-B. Here 
as well, pIR8 and pcBF8 improved clotting better than phBF8 though the overall efficacy 
by the lentiviral approach is less than in the transgenic approach as these reconstituted 
mice have lower pFVIII levels as shown in Figure 2.8A-B, and also have lower steady-
state platelet counts. Likewise, the ubiquitin promoter-driven constructs have 
concurrent low levels of plasma pIR8 or pcBF8 (Figure 2.8A-B), but these were again no 
more effective (and likely less effective) in improving hemostasis in this injury model 
than mPF4 promoter-driven constructs with no plasma FVIII, p > 0.5 for ubiquitin 
versus PF4 for each variant (FuhF8 vs FPhF8, FUIR8 versus FPIR8, and FUcF8 vs 
FPcF8). For the time to occlusion studies only IR8 was significantly different, p < 0.04, 
while the other two variants had p > 0.07.  
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Figure 2.11: BMT/Lenti FVIIInull mice FeCl3 carotid artery studies. (A) Average 
blood flow and (B) average time to occlusion over 30 mins. Grey horizontal bars = the 
mean ± 1 SD for time to occlusion in WT (lower horizontal grey bar) and FVIIInull (upper 
horizontal grey bar) mice. N > 8 mice per arm. * = p <0.02 and ** = p <0.002 for 
ubiquitin (U) (blue bars)- and mPF4 (P) (pink bars) -promoter driven vector mice 
relative to FVIIInull mice.  
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2.4.4 Cremaster Muscle Arteriole and Venule Laser-Injury Model 
To study arteriole versus venule efficacy of pFVIII variants, hBF8, IR8 and cBF8, we 
used the in-situ laser-induced cremaster arteriole/venule injury system previously 
described (116). Studies of arteriole and venule laser injury in WT and in FVIIInull mice 
were consistent with published studies as illustrated in Figure 2.12A-B (18, 30, 116). WT 
mice had an immediate accumulation of platelets in arterioles and venules and 
approximately a 20-second and 40-second delay before significant fibrin accumulation 
in arterioles and venules, respectively. FVIIInull mice had little platelet and fibrin 
accumulation in both arterioles and venules over the time frame of this study. 
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Figure 2.12: In situ cremaster arteriole and venule control studies. Average 
data for platelet (green) and fibrin (red) accumulation. The number of injuries and mice 
studied are shown. Control mice were: (A) WT and (B) FVIIInull mice. 
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Line phF8.38/FVIIIInull showed a partial correction of platelet and fibrin 
accumulation (Figure 2.13A), consistent with published studies (116). pIR8.5/FVIIInull 
appeared to not be as effective at fibrin accumulation as phF8.38/FVIIInull seen in Figure 
2.13B; however, while hBF8 fibrin accumulation rapidly plateaued on the arteriole side, 
pIR8 fibrin curve continued to accumulate with time as seen in a separate 5-minute 
study in Figure 2.14. This observation reflects the stability of IR8 in vitro and is 
consistent with IR8 being resistant to inactivation and showing prolonged activity in 
vitro. On the other hand, pcF8.24/FVIIInull showed platelet accumulation and fibrin 
incorporation almost as well as WT mice (Figure 2.12A, and Figure 2.13C). Time of onset 
of fibrin accumulation was better than with the pIR8.5 an phF8.38 FVIIInull transgenic 
mice as shown in Figure 2.13, especially in the venules. Thus, pcBF8- despite having a 3-
fold lower level of pFVIII- showed an improved hemostasis in this bleeding model 
compared to the other variants. 
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Figure 2.13: In situ cremaster arteriole and venule pFVIII/FVIIInull 
transgenic mice studies over a 2.5-minute window. Average data for platelet 
(green) and fibrin (red) accumulation. The number of injuries and mice studied are 
shown. Transgenic lines phF8.38 (A), pIR8.5 (B), and pcF8.24 (C) on a FVIIInull 
background were studied. 
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Figure 2.14: In situ cremaster arteriole and venule 5-minute studies for 
pIR8.5/FVIIInull mice. Average data for platelet (green) and fibrin (red) accumulation. 
The number of injuries and mice studied are shown. (A) phF8.38 and (B) pIR8.5 on a 
FVIIInull background were studied. 
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2.4.5 Embolization Studies 
Previous studies showed that phF8.38/FVIIInull was associated with an increased risk of 
clot embolization in the cremaster laser injury model. We now tested whether either 
pIR8 or pcBF8 had fewer emboli. Studies of WT and untreated FVIIInull mice gave 
similar arteriole and venule results to what had been previously reported (116) as shown 
in Figure 2.15. Our studies of IR8 showed that pIR8.5/FVIIInull mice had the same degree 
of embolization as phF8.38/FVIIInull mice, Figure 2.15A. In contrast, even though the 
pcF8.24/FVIIInull mice had an ~3-fold lower pFVIII levels than phF8.38/FVIIInull mice, 
they had a marked decrease in both arteriole and venule embolization. This 
improvement was especially clear for embolic size as illustrated in Figure 2.15B and for 
total embolic mass in Figure 2.15C. 
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Figure 2.15: Embolization studies after cremaster arteriole and venule 
injuries. Embolization studies downstream of arteriole and venule injuries. (A) Number 
of detectable emboli. (B) Average relative embolic size determined by mean fluorescence. 
(C) Total embolic mass per study determined from the number and size of emboli. All 
transgenic are on a FVIIInull background. Red bars = arteriole studies and blue bars = 
venule studies. N > 18 movies per arm. Mean ± 1 SD shown. * = p <0.035 relative to WT. 
** = p <0.04 relative to phF8.38.  
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2.4.6 Inhibitor Studies of pIR8  
One of the greatest challenges in the care of hemophilia A is the management of patients 
with inhibitors. Since plasma IR8 is not protected from inhibitors by binding to vWF 
(134), we examined whether pIR8 is as effective in FVIIInull mice as phBF8 in the 
presence of inhibitors. We tested the pIR8.5/FVIIInull mice in the FeCl3 system when 
challenged with a FVIII antibody model compared to phF8.38/FVIIInull transgenic mice. 
In these studies, the mice were repeatedly infused with FVIII inhibitor mixture over a 9-
day schedule to allow steady-state levels of the inhibitors to accumulate in the platelets 
(41). In the chronic mixed monoclonal inhibitor study, pIR8 was protected from the 
inhibitors, but only to the same extent as phBFVIII seen in Figure 2.16 “MoAb”. Because 
ESH8 inactivation of IR8 may be complex (134, 155), we also tested pIR8 and phBFVIII 
after a similar infusion schedule using IgG purified from human FVIII-deficient plasma 
with inhibitors and showed that pIR8 had greater resistance to this inhibitor than 
phBFVIII as shown in Figure 2.16 “Human”.  
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Figure 2.16: Inhibitor studies in pIR8.5/FVIIInull mice. FeCl3 carotid artery 
injury studies in phF8.38/FVIIInull mice (pink bars), and pIR8.5/FVIIInull mice (blue 
bars). In (A and B) on the left is an acute study where the animals received a one time 
infusion of the inhibitor mix, and in the middle are chronic studies done on day 10 of 
study after a murine IgG control or murine inhibitor mix infusions of FVIII on days 0, 3, 
6 and 9. On the right are chronic studies done using inhibitor IgG purified from FVIII-
deficient plasma. In (A) and (B) mean ± 1 SD are shown for N >5 mice per arm. Results 
in (A) are expressed as average blood flow seen. Studies in (B) show the time to 
occlusion. * = p <0.025 and ** = p <0.05 relative to phF8.38. Grey horizontal bars in (A) 
and (B) = the mean ± 1 SD for WT (lower) and FVIIInull (upper) mice.  
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2.5 Discussion 
Present day management of severe hemophilia A with early introduction of recombinant 
FVIII prophylaxis in childhood has reduced the incidence of chronic joint and other 
bleeding manifestation complications (130). Among the remaining challenges in the care 
of hemophilia A is the development of inhibitors in up to 30% of these individuals (193). 
The recent recognition that early exposure to FVIII increases one’s risk of developing 
inhibitors has only further sharpened the need to find effective therapies for this 
complication beyond induction of tolerance strategies (4, 96, 193). Shi et al first showed 
(165), and we confirmed (41), that pFVIII is protected from circulating inhibitors. Our 
previous data suggest that pFVIII is 100-fold more effective than plasma FVIII in the 
presence of inhibitors in spite of the co-presence of the inhibitors within the platelets 
(41). 
 However, while ectopic expression of FVIII within platelets may offer a potential 
advantage in the presence of inhibitors (26, 101), this strategy has certain limitations. 
One clear disadvantage is that platelet activation needs to occur to release pFVIII. We 
have shown that the availability of the pFVIII is dependent on platelet degranulation, 
and this process is delayed within a growing clot, begins at its base and then slowly 
spreads throughout the clot (41). We believe that this temporal and physical 
maldistribution of FVIII underlies the increased rate of clot embolization we saw in 
FVIIInull mice expressing phBF8 in the cremaster laser arteriole/venule injury model. We 
now tested whether this risk of embolization could be improved or eliminated by using 
FVIII variants, IR8 and cBFVIII, each with increased specific activity. 
 Our data show that both variants showed promise: pIR8 levels and releasibility 
after activation were comparable to phBF8 by both transgenic and BMT/Lenti 
approaches in spite of IR8’s inability to bind vWF (134). It was significantly more 
effective than phBF8 in both the FeCl3 and cuticular clotting models in the FVIIInull 
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setting, reflecting IR8’s resistance to spontaneous A2-domain dissociation and 
proteolytic inactivation. However, in the cremaster laser injury system, IR8 was no 
better than phBF8. Consistent with this limited degree of improvement in this clotting 
model, pIR8/FVIIInull mice had as much embolization as the phBF8/FVIIInull mice. We 
believe that this difference in pIR8 efficacy in the various models tested may be 
explained by the fact that FVIII normally may be sequentially activated by thrombin with 
R740 cleavage occurring before R372 (115). IR8 was engineered with mutations at thrombin 
sites for R740 and R1689, such that its full-activated potential is after cleavage at R372 (134). 
A recent study showed that introducing two point mutations at the R740 cleavage site of 
FVIII drastically decreases the rate of A2 subunit generation with a 20-fold reduction in 
the cleavage rate at R372 (115), suggesting an ordered reaction mechanism for the 
activation of FVIII. This R740A mutation in IR8 therefore may slow cleavage at R372 so 
that this mutation in IR8 may protect it from inactivation (134), but also may slow 
activation, as supported by the need to have a longer cremaster study to see efficacy as in 
Figure 2.13. We propose that the cuticular and FeCl3 injuries are both more diffuse 
injuries allowing wider zones of pIR8 release and also have endpoints only after a much 
longer time period than in the cremaster studies that are confined within the site of 
injury, so that the initial slow activation of IR8 is not appreciated.  
 The pIR8 studies also provide additional insight into the biology of megakaryocyte-
expressed FVIII, since it minimally binds vWF and could potentially be poorly stored in 
α-granules and also more susceptible to inhibitors than phBF8. These pIR8 studies 
support our prior studies with vWF-/- mice that pFVIII α-granule storage and release 
from activated platelets is mostly independent of concurrent vWF expression and storage 
(196). We also found that pIR8 retains its effectiveness in the presence of anti-FVIII 
inhibitors, supporting that vWF binding is not essential for pFVIII efficacy in the 
presence of circulating inhibitors. These findings are consistent with the evolving 
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concept that there are separate platelet granule pools within platelets (63), and perhaps 
pFVIII has limited intra-platelet contact with the endocytosed inhibitors and may have 
different time or spatial release as well. These inhibition observations may also be 
important in large animal studies of pFVIII. The FVIIInull canine model is the best-
studied large animal model for hemophilia A (58). Prior studies suggest that these 
animals have little to no platelet vWF (97, 127). Since IR8 does not bind vWF well, we 
believe that our studies support the ability to use this large animal hemophilia A model 
to study pFVIII biology, including inhibitor studies. 
 Canine BFVIII was a potential candidate as a platelet-expressed FVIII because it 
had both increased specific activity and higher expression levels than hBF8 when studied 
in BHK cells (152). The bases for these species differences have yet to be determined. We 
found that pcBFVIII expressed in mice demonstrated increased specific activity, but was 
expressed at a decreased level in megakaryocytes and platelets. Overall, there was a 1.7 
times increase in the pFVIII activity in the pcF8.24 line relative to phF8.38, roughly 
equal to the increase in the pIR8 transgenic mice as shown in Figure 2.9. Like pIR8, 
pcBFVIII was significantly more effective than phBFVIII in the cuticular and FeCl3 
carotid artery clotting models; however, unlike pIR8, pcBFVIII was also more effective in 
the cremaster laser injury model, both on the arteriole and venules sides. This 
observation was supported by the embolization studies in which the cBFVIII was the first 
pFVIII studied that had almost normal embolization size and total mass in the FVIIInull 
setting.  
 The molecular basis of why pcBFVIII was effective in the cremaster model and 
pIR8 was not as effective is not apparent. Similarly, the basis for the lower level of 
pcBFVIII relative to the levels seen with the phFVIIIs is also unclear. This observation of 
low pcBFVIII could be due to RNA message level, but the same cDNAs were used in the 
baby hamster kidney cell expression studies, where cBFVIII was expressed at levels 
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several fold higher than hBFVIII (152). More likely the underlying defect in pcBF8 levels 
is related to the well-known difficulty for FVIII to undergo intracellular processing, 
leading to intracellular accumulation and cellular apoptosis. This concept is one of the 
foci of the studies discussed below in Section 3. 
 Finally, the possibility exists that because platelet- and plasma-delivered FVIII 
may have different physical and temporal availability that low levels of plasma FVIII may 
have a synergistic effect with pFVIII. This concept was tested in the cuticular and FeCl3 
clotting models using transgenic mice with equal levels of platelet, but different levels of 
plasma FVIII, e.g., pIR8.16/FVIIInull and pIR8.18/FVIIInull, wherein the pIR8.18 mice 
have plasma as well as platelet FVIII. In both models, pIR8.18/FVIIInull was at best 
slightly more effective than pIR8.16/FVIIInull. These data are supportive that pFVIII is 
effective in these models and that there was not a major synergistic benefit of concurrent 
low levels of plasma FVIII. 
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2.6 Conclusion 
We have found that pIR8 is more effective than phBFVIII in several clotting models in 
FVIIInull mice, but that it did not improve clot instability in the cremaster 
arteriole/venule laser injury system, perhaps because of its slow rate of fibrin onset. On 
the other hand, we tested the possdespite IR8 not being able to bind to vWF was not 
needed for IR8 protection from circulating inhibitors. We also showed that pcBFVIII is 
even more effective in improving clotting in the murine FVIIInull model even though the 
level of pcBFVIII achieved in megakaryocytes was a third of phBFVIII. In spite of this 
lower level of expression, pcBFVIII was the first FVIII to correct clot instability in the 
cremaster injury model in FVIIInull mice. Determination of the basis of the efficacy of 
pcBFVIII in this setting may be useful in bringing platelet-based gene therapy for 
hemophilia A to clinical fruition and may have been achieved with a modification of 
hBFVIII to simulate a known property of cBFVIII as discussed in the next section. 
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Chapter 3 
Intracellular Processing of Factor VIII During Megakaryopoiesis 
 
3.1 Abstract 
We demonstrated that FVIIIs, such as cBFVIII, with greater specific activity than 
hBFVIII, would prevent pFVIII clot instability. However at the same time, pcBF8 levels 
were only ~30% of phBF8 whether studied in transgenic mice models or by BMT/Lenti 
studies in FVIIInull mice. This was surprising because in BHK cells, cBFVIII was secreted 
into the media at three times greater amount than hBFVIII. This lower level of cBFVIII 
in murine megakaryocytes was not due to lower mRNA levels as we now show by qRT-
PCR analysis. Using cultured marrow from transgenic mice expressing hBF8 or cBF8, 
there was a marked decrease in relative number of megakaryocytes in both pFVIIIs 
compared to WT (FVIIInull), but especially for cBF8. We then tested whether we can 
separate the greater specific activity affect of pcBF8 from its deleterious affect on 
megakaryopoiesis. Our colleague, Dr. Arruda, has previously shown that cBFVIII may 
have increased stability because it is predominantly expressed as a single chain, likely 
involving the R1645H substitution at a conserved PACE/furin site, which is not present in 
FVIII species other than dog. They found that hFVIIIR1645H had decreased two-chain to 
single chain FVIII production in BHK cells. BMT/Lenti pFVIII studies expressing 
phBF8R1645H showed that this pFVIII was expressed at the same level in reconstituted 
mice as phBF8, but was more efficacious in several hemostatically normal models, 
including near-normal hemostasis in the cremaster laser injury model in FVIIInull 
recipient mice, thus becoming the first BMT/Lenti pFVIII-expressing FVIIInull mouse 
with near-normal hemostasis in a FVIIInull setting. 
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3.2 Background 
In our initial studies of pFVIII variants in FVIIInull mice, we showed that pcBF8 was 
more effective at improving clotting, and was the only variant to correct clot instability as 
described in Section 2 (49). However, cBFVIII expression level was ~30% of the other 
variants hBFVIII and IR8. While conducting these studies, Dr. Arruda’s group at the 
University of Pennsylvania did an in vitro comparative study of hBFVIII and cBFVIII to 
begin to characterize and address the biological properties of cBFVIII. They found that 
the expression of cBFVIII in BHK cells was 3-fold higher than hBFVIII, and that cBFVIII 
was predominantly expressed as a single-chain form (152). Interestingly cBFVIII levels 
corresponded to a 3-5-fold increased specific activity, and rapid activation by FIIa 
showed that the half-life of cBFVIIIa was 3-fold longer than hBFVIIIa as well (152). On 
the basis of this, Dr. Arruda’s group hypothesized that the increased specific activity of 
cBFVIII is likely involves the intracellular stability of the single-chain protein through its 
PACE/furin recognition site HHQR, which is under investigation. 
FVIII processing and transport from the ER to the Golgi apparatus is very 
complex as described in Section 1.1.2.2. Because FVIII is known to have intracellular 
defects in processing and the same cBFVIII cDNA were used in our transgenic studies 
and the BHK cells studies, we hypothesized that the deficiency in cBF8 expression in 
megakaryocytes is likely due to the inability of FVIII to be effectively processed in the 
ER. FVIII processing involves the initial translocation of FVIII to the lumen of the ER 
where it undergoes N-glycosylation and subsequent glucose trimming via the CXN/CRT 
to ensure proper folding (29). Properly folded FVIII is transported to the Golgi via 
vesicular transport of the LMAN1/MDFC2 receptor complex (198) as shown in Figure 1.2 
and Figure 3.1A, where it further proteolytically processed to ensure proper secretion. 
However, as mentioned previously, FVIII is susceptible to mis-folding in the ER and 
binds the ER stress protein BiP resulting in a decreased efficiency of FVIII secretion 
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from the cell (169). In non-stressed cells, the repression of apoptosis is through the 
binding of BiP to unfolded protein response (UPR) sensors inositol requiring kinase 1 
(IRE1), double stranded RNA-activated protein kinase-like-ER kinase (PERK) and the 
transcription factor-activating factor 6 (ATF6) (8, 92). However in a stress-induced 
environment unfolded proteins such as FVIII bind BiP, and release BiP from the UPR 
sensors. This in turns activates the UPR sensors and activates the UPR pathway (46, 117) 
ultimately leading to cellular apoptosis as shown in Figure 3.1B. A recent study was 
instrumental in our understanding of the relationship between FVIII protein mis-folding 
in the ER and the induction of apoptosis (93). This study found that accumulation of 
unfolded FVIII within the ER of Chinese hamster ovary (CHO)-H9 cells led to the 
activation of the UPR pathway, causing oxidative stress and apoptosis. This FVIII 
malfolding can be exacerbated by sodium butyrate (NaB), leading to cellular apoptosis 
(93). The anti-oxidant, butylated hydroxyanisole (BHA), can reverse this apoptosis. 
Below, we use NaB to exacerbate the deleterious effect of pFVIII on megakaryopoiesis 
and BHA to reverse that effect and show that of all the pFVIIIs, pcBFVIII was most 
deleterious suggesting that in murine megakaryocytes the limited pcBFVIII level is due 
to its increased malfolding. 
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Figure 3.1: The ER and the unfolded protein response (from Randal. J Kaufman 
(92)). (A) Protein trafficking in the ER as described in Section 1.1.2.2. (B) Signaling the 
unfolded protein response. Three proximal sensors inositol requiring kinase 1 (IRE1), 
double stranded RNA-activated protein kinase-like-ER kinase (PERK) and the 
transcription factor-activating factor 6 (ATF6) regulate the UPR through their respective 
signaling cascades that induces the expression of anti-oxidative stress response genes 
and expression of genes encoding proteins with apoptotic functions. 
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 In the biological studies of cBFVIII, it was noted that cBFVIII amino acid 
recognition sequence for intracellular cleavage by PACE/furin (HHQR) differs from 
human and porcine FVIII (RHRQ). To begin to test the possible role of this cleavage site 
in increased cBFVIII single chain stability and activity, reciprocal amino acid 
substitution was introduced into hBFVIII and cBFVIII cDNA pED vector using 
QuickChange XL Site-Directed Mutagenesis Kit (Stratagene La Jolla, CA). This single 
amino acid substitution of RH in hBFVIII and HR at a position homologous in 
cBFVIII resulted in a shift of ~2-3 fold in the ratio of single chain to cleaved FVIII in the 
secreted material in the anticipated direction as shown in Figure 3.2A (courtesy of Dr. 
Arruda). Moreover, activated hBFVIIIR1645H had a 3-fold increase in half-life compared 
to activated WT hBFVIII as shown in Figure 3.2B. These studies suggest that a single 
amino acid substitution may enhance phBFVIII stability and is the focus of the lentiviral 
studies addressed in this section. 
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Figure 3.2: Preliminary characterization of recombinant hBFVIIIR1645H and 
cBFVIIIH1637R (courtesy of Valder Arruda). Reciprocal amino acid substitution was 
introduced into hBFVIII and cBFVIII cDNA. (A) Coomassie blue stain of a reducing 
SDS-PAGE gel hF8= hBFVIII; hRH= hBFVIIIR1645H; cF8= cBFVIII; and cHR= 
cBFVIIIH1637R. (B) A2 domain disassociation of hBFVIII and hBFVIIIR1645H were 
compared using a reconstituted Xase complex assay. Mean ± 1 SE of 3 experiments, each 
done in duplicate. 
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3.3 Materials and Methods Used 
3.3.1 Quantitative Real Time PCR (qRT-PCR) 
FVIII message level was detected in platelets and cultured bone marrow megakaryocytes 
of our highest pFVIII/FVIIInull mice for hBF8 (hF8.38) and for cBF8 (cF8.24). Platelets 
were isolated from vena cava puncture as described (49). For megakaryocyte studies, 
bone marrow cells were harvested from the femur and tibia of 8-to-12 week old cF8.24 
and hF8.38 FVIIInull transgenic mice. The harvested bone marrow cells were cultured for 
up to 7 days at 37°C in 5% CO2 in Iscove’s Modified Dulbecco’s Media (IMDM) 
supplemented with 1% PS, 1% LG (all GIBCO BRL), 1% nutridoma (Roche Applied 
Science, Indianapolis, IN), 50 µM final of β-mercaptoethanol (Sigma Aldrich, St. Louis, 
MO) and 50 ng/ml final of recombinant mouse (rm) thrombopoietin (TPO) (Research 
Diagnostics, Acton, MA) to induce megakaryocyte formation. Total RNA was isolated as 
described (49) using RNA-Stat 60 extraction methods. Purified RNA was reverse 
transcribed using Superscript II as per the manufacturer's instructions (Life 
Technologies, Bethesda, MD) and treated with RNase H before use in RT-PCR. Primer 
sequences for quantitative real time PCR (qRT-PCR) studies were GPIbα exon 1 (5’-
TCTGTTCCTCCAAAGGACTG-3’) sense primer and an hBFVIII/cBFVIII common coding 
region (5’-TCACTTTGCATATAGTCC-3’) antisense primer. cF8.24 FVIII mRNA level was 
normalized to α-tubulin or GAPDH or PF4 mRNA level for hF8.38 mice.  
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3.3.2 Apoptosis Studies in pFVIII Transgenic Mice Megakaryocytes 
Bone marrow cells were extracted from murine femurs and tibia of hF8.38, and cF8.24 
FVIIInull transgenic mice. Bone marrow megakaryocytes were prepared as described in 
the previous section. On day 5 of culture with rmTPO, the cells were split into three 
experimental conditions for untreated cells, NaB treated at 5 mM final, and NaB 
supplemented with BHA at 10 µM final. rmTPO was added at 50ng/ml final to each 
experimental condition, and the megakaryocytes were allowed to grow for an additional 
24 hrs. The next day the cells were collected, spun at 400g for 5 mins, resuspended in 
PBS, then split into two aliquots one, for apoptosis analysis and one for ploidy analysis.  
For apoptosis studies, cultured megakaryocytes were stained with 0.5 µl of anti-
CD41 Fab fragments conjugated with Alexa647 (as described in Section 2) for 30 mins on 
ice. Apoptosis assessment was done using terminal deoxynucleotidyl transferase (dUTP) 
nick-end labeling (TUNEL) using an Apo Direct Kit (BD Pharmingen Franklin Lakes, 
NJ) as per manufacturer instructions. Cells were suspended in 1% paraformaldehyde in 
PBS (pH 7.4) and placed on ice for 30-60 mins, then washed 2x with 5 ml of PBS by 
centrifugation at 300g for 5 minutes. Cells were then resuspended in 70% ice-cold 
ethanol and placed on ice for a minimum of 30 mins. Cells were washed with 1 ml of 
wash buffer, resuspended in 50 µl of DNA labeling solution (10 µl of reaction buffer, 0.75 
µl of terminal deoxynucleotide transferase (TdT) enzyme, 8 µl of FITC labeled 
deoxyuridine triphosphates (FITC-dUTP) and 32 µl of dH20), and incubated for 60 mins 
at 37°C. Cells were rinsed with 1 ml of rinse buffer, and resuspended in 500 µl of 
propidium iodine (PI)/RNase staining buffer for 30 mins. Each sample was analyzed by 
flow cytometry for the number of CD41+ megakaryocytes and the number of FITC-dUTP 
positive megakaryocytes.  
For ploidy analysis, samples were resuspended in 50 µL CATCH buffer (0.38% 
sodium citrate, 2 mM theophylline, 1 mM adenosine, 3.5% BSA in PBS) and labeled with 
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1 µl of anti–CD41-FITC for 30 mins. The cells were then washed with 10 volumes of 
CATCH buffer and spun at 70g for 10 mins. Afterward, the cells were resuspended in 400 
µl hypotonic propidium iodide solution (0.1% sodium citrate with 50 µg/ml propidium 
iodide) and incubated at 4°C overnight. Thirty mins before flow cytometry, RNAse A was 
added at 50 µg/ml final concentation at room temperature. Data for all flow cytometric 
studies were collected using a FACSCalibur machine and analyzed using CellQuest 
software. 
 
3.3.3 FPhF8R1645H Lentiviral Studies 
The R1645H mutation was introduced into our previously described (49) mPF4 promoter-
driven hBFVIII (FPhF8) lentiviral vector using the same mutagenesis methodology 
employed by Dr. Arruda’s group. Lentiviral stocks for FPhF8R1645H were produced as 
described in section 2.3.2 (49), transduced into FVIIInull bone marrow cells, and injected 
into lethally irradiated hαIIb/FVIIInull mice following the exact method described earlier. 
Control mice received FPhF8 and FPcF8 virus. The degree of chimerism was determined 
in recipient mice by flow cytometry, and FVIII antigenic levels were measure in platelet 
lysate as described earlier. The in vivo functionality of the R1645H mutation was tested in 
the FeCl3 and cremaster laser injury models described earlier. Embolization studies were 
carried out as described above.  
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3.4 Results 
To address the inefficiency of platelet ectopic expression of cBFVIII and its increased 
specific activity, we examined cBFVIII mRNA level in developing murine 
megakaryocytes and platelets of our pcBF8 transgenic mice cF8.24/FVIIInull. We found 
that cBFVIII mRNA was similar to hBFVIII mRNA by qRT-PCR. Apoptosis studies 
showed all pFVIII lines had increased apoptosis, but that despite having ~70% reduction 
in protein levels, pcBF8 had the highest degree of apoptosis compared to hBF8. To test 
the importance of the PACE/furin cleavage in the hemostatic effectiveness of cBFVIII, 
we introduced a single amino acid substitution of RH into the hBFVIII PACE/furin 
site. We found that this hBFVIIIR1645H mutant had an increased specific activity in vivo 
relative to hBFVIII following FeCl3 injury. We also observed a marked increased in fibrin 
incorporation into a growing thrombus in the cremaster laser injury model. Preliminary 
embolization studies suggest a decrease in clot instability, therefore making this FVIII 
construct a strong candidate for pFVIII therapy trials in a large animal model. 
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3.4.1 qRT-PCR  
To begin to understand the mechanistic basis for low cBFVIII expression during 
megakaryopoiesis, we determined FVIII RNA message level in the highest expressing 
transgenic line for pcBF8 (pcF8.24) and compared to phF8.38 both in developing 
megakaryocytes and platelets. pcF8.24 FVIII mRNA level was normalized to phF8.38 
separately for the housekeeping genes GAPDH and α-tubulin, and for PF4 as shown in 
Figure 3.3. Our studies show that the decreased cBFVIII level detected in the platelets of 
our cBF8 transgenic mice is not due to mRNA levels, as pcF8.24 levels were ≥75% of 
hF8.38 by these 3 analyses. Moreover, the level of pcBFVIII message was not worse in 
platelets than megakaryocytes suggesting that the message stability of pcBFVIII is no 
different than phBFVIII message, p > 0.5. 
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Figure 3.3: FVIII mRNA levels in platelets and megakaryocytes of 
pcF8.24/FVIIInull mice. qRT-PCR analysis of FVIII expression in developing murine 
megakaryocytes (red bars) and isolated platelets (blue bars), by real-time qRT-PCR of 
pcBF8.24/FVIIInull mice normalized for α-tubulin, GAPDH, and PF4. Plotted as fold 
change from phF8.38/FVIIInull mice, N > 4.  
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3.4.2 Apoptosis in pFVIII Transgenic Mice Megakaryocytes 
To study the known intracellular effect of FVIII on megakaryocyte biology, we examined 
the effect of pFVIII expression in megakaryocytes to induce apoptosis. We treated 
megakaryocytes in culture for 5 days with NaB, a histone deactylase inhibitor that was 
shown to increase the synthesis of FVIII mRNA and protein, with the majority of the 
newly synthesized FVIII aggregating into a complex with BiP (171). To increase the 
secretion efficiency of FVIII we supplemented the NaB treated megakaryocytes with 
BHA, a lipid-soluble antioxidant that’s has been shown to suppress TNFα-induced cell 
death (184) and increase FVIII secretion (171). 
We found that treatment with NaB decreased megakaryocyte formation in all the 
pFVIIIs tested, relative to WT control. However, there was an even more significant 
decrease in megakaryocyte formation in the cF8.24 mice relative to hF8.38 mice as 
shown in Figure 3.4A, (p < 0.015). Treatment of the cells with BHA reversed this effect, 
with cF8.24 megakaryocyte production no longer being statistically different from 
hF8.38. Using TUNEL to assess the degree of apoptosis we found that despite cBF8 
being expressed in platelets at ~70% less than hBF8, its expression in megakaryocytes 
led to the highest degree of apoptosis though significant differences were not achieved. 
Adding BHA to NaB treated megakaryocytes again reversed this effect, with cF8.24 
showing the most prominent decrease in apoptosis (Figure 3.4B).  
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Figure 3.4: pcBF8 expression shows increased apoptosis in cultured 
bone marrow megakaryocytes. Apoptosis studies in pFVIII transgenic lines (A-
B). (A) The mean ± 1 SD for the number of CD41 positive megakaryocytes in culture 
when treated with NaB (red bars), p <0.015 for pcF8.24 relative to phF8.38, and 
NaB treatment supplemented with BHA (blue bars). (B) The mean ± 1 SD for CD41 
positive megakaryocytes that is positive for the apoptosis marker dUTP-FITC 
(TUNEL). Results are plotted as the fold change from WT, N > 8. 
We assumed that as pFVIII likely accumulates into maturing megakaryocytes 
that pFVIII would be more deleterious to high ploidy megakaryocytes. To examine DNA 
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content for megakaryocytes in culture with NaB, we defined low ploidy megakaryocytes 
as the combined 2N+4N population of CD41+ megakaryocytes. For NaB treated 
megakaryocytes we found that all the pFVIII variants increased low ploidy 
megakaryocytes relative to WT control as shown in Figure 3.5. This increase was more 
pronounce for the cF8.24 transgenic line, supporting that pcBFVIII is most deleterious 
to maturing megakaryocytes. Treatment with BHA resulted in a decrease in the number 
of low ploidy megakaryocytes in culture, again consistent with a less deleterious affect on 
megakaryocyte development.  
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Figure 3.5: pFVIII synthesis in cultured megakaryocytes increases low 
ploidy megakaryocytes especially for pcBF8. The number of low ploidy 
(2N+4N) CD41 positive megakaryocytes in culture when treated with NaB (red bars) 
and NaB treatment supplemented with BHA (blue bars). Results are plotted as the 
mean ± 1 SD for the fold change from WT, N > 4.  
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3.4.3 BMT/Lenti Chimeric Studies 
 One would also expect that after BMT/Lenti that the pcBFVIII mice would have 
difficulty re-establishing a normal platelet count and would have more recipient platelets 
in the steady-state recovered mouse. A retrospective analysis of our BMT/Lenti studies 
did not show that there was a delay in recovery of any line, but a prospective analysis is 
needed to be definitive. We did find that the pcBFVIII BMT/Lenti mice clearly had the 
highest level of recipient platelets (Figure 3.6A) and the same was observed in our prior 
studies with the ubiquitin expressing variants (1.9 ± 1.2, 4.8 ±0.8 and 9.0 ± 1.6 % for 
FUhF8, FUIR8, and FUcF8 respectively). This raises the concern that pFVIII being 
deleterious to megakaryopoiesis can affect platelet recovery in the clinical setting and the 
need to be careful to use a least deleterious construct.  
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3.4.5 Effectiveness of FPhF8R1645H BMT/Lenti Studies 
Based on the above observations, we wondered whether introducing the canine 
PACE/furin cleavage site mutation in hBFVIII would enhance phBFVIII efficacy without 
affecting level. We found that the incorporation of the cBFVIII PACE/furin recognition 
site into hBFVIII did not affect antigenic levels as shown in Figure 3.6B (FPhF8 
compared to FPhF8R1645H). Moreover, the level of recipient platelets in BMT/Lenti-
phBFVIIIR1645H reconstituted mice was no different than with phBFVIII (Figure 3.6A). 
 We tested the in vivo functionality of this R1645H mutation using the FeCl3 and 
cremaster models described earlier. In the FeCl3 model, our initial studies were done 
with a standard injury of 20% FeCl3 for 4 mins that we had determined for our prior 
BMT/Lenti studies (49). We found that the FPhF8R1645H expressing mice had a normal 
clot formation compared to the other BMT/Lenti mice as shown in Figure 3.6C (open 
bars). We used less chemosclerotic injuries of 20% FeCl3 for 2 mins and 15% FeCl3 for 4 
mins, and showed that FPhF8R1645H continued to have an even better improvement in 
clotting after these milder injuries relative to unchanged hBF8 (FPhF8) as shown in 
Figure 3.6C (grey and black bars).  
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Figure 3.6: BMT/Lenti studies for FPhF8R1645H (A-C). (A) The percent recipient 
platelets post-BMT. (B) Antigenic levels in platelet lysate were measured, and (C) FeCl3 
studies. * = p <0.05 for FPhF8R1645H relative to FPhF8. All mice were FVIIInull. 
Background measurements in FVIIInull mice were subtracted in (A) and (B). Mean ± 1 SD 
are shown. The number of animals in each arm is shown above each bar.  
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 To examine arteriole and venule efficacy of the FPhF8R1645H variant ability to 
incorporate fibrin into a growing thrombus, we used the in-situ cremaster model (49). 
We performed studies in WT and FVIIInull control mice and confirmed previously 
published studies by us (49, 116) and by others (18, 30) (refer to Figure 2.12 if 
necessary). Again, WT mice had an immediate accumulation of platelets and fibrin in 
both arterioles and venules, while FVIIInull mice had a diminished platelet accumulation 
and fibrin incorporation. For the BMT/Lenti mice, FPhF8R1645H expressing mice had 
better platelet incorporation in arterioles and venules, and markedly improved fibrin 
incorporation relative to the FPhF8 or FPcF8 studied in parallel (Figure 3.7). These 
findings are the most improved outcome to date for either transgenic or BMT/Lenti 
studies we have seen in all the variants we have tested. Embolization studies are 
preliminary, and suggest a decrease in clot instability (Figure 3.8), however studies with 
BMT/Lenti FVIIInull mice for FPhF8 and FPcF8 have to be completed to draw a full 
conclusion.  
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Figure 3.7: Fibrin and platelet incorporation into a growing thrombus for 
FPhF8R1645H. Average data for platelet (green) and fibrin (red) accumulation. The 
number of injuries and mice studied are shown. BMT/Lenti mice (A) FPhF8, (B) FPcF8 
and (C) FPhF8R1645H on a FVIIInull background were studied over 3 min. The number of 
mice and injuries are listed in the figure. 
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Figure 3.8: Preliminary embolization studies for FPhF8R1645H. Embolization 
studies downstream of arteriole and venule injuries. (A) Number of detectable emboli. 
(B) Average relative embolic size determined by mean fluorescence. (C) Total embolic 
mass per study determined from the number and size of emboli. Open bars = arteriole 
studies and closed bars = venule studies. N > 8 movies per arm. Mean ± 1 SD shown.  
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3.5 Discussion 
Our apoptosis findings show that accumulation of FVIII in the ER lumen is sufficient to 
activate the UPR pathway and induce apoptosis when pFVIII variants are expressed 
during megakaryopoiesis. Our results confirm the findings of a recently published study 
that suggests that cell death in the ER is perpetuated by ER stress that is induced by the 
accumulation of unfolded FVIII in the ER, and by oxidative stress caused by the 
generation of reactive oxygen species (93). This increased apoptosis was accentuated for 
cBFVIII, even though cBFVIII was expressed at much lower levels than the hBFVIII. We 
also confirmed that the addition of the antioxidant BHA to megkaryocytes in culture with 
NaB significantly reversed this apoptotic effect (93). To support these apoptosis studies 
of pcBF8, our chimeric lentiviral studies, showed that the PF4 expression of cBFVIII in 
platelets resulted in a much higher percentage of recipient platelets (Figure 3.7A). This 
effect was also observed in the ubiquitously expressing pcBFVIII mice (data not shown). 
These findings raise the concern that pFVIII would be deleterious to platelet recovery in 
the clinical setting with the need to be careful to use the least deleterious pFVIII 
construct. It also suggests that there may be a limit to total pFVIII one can achieve so 
that an approach to increase pFVIII specific activity rather than level may be needed to 
bring the pFVIII approach to clinical fruition. 
The R1645H mutation was a potential candidate for incorporation into our pFVIII 
variant studies, as Dr. Arruda’s group first demonstrated in preliminary in vitro studies 
that the increased specific activity of cBFVIII (152) relative to hBFVIII was reflective of 
the PACE/furin site in cBFVIII (Figure 3.2). We found that expression of the R1645H 
mutation in platelets of FVIIInull BMT/Lenti mice did not affect platelet antigenic FVIII 
levels. This suggests that the PACE/furin site in cBFVIII does not affect the low 
expression levels of pcBF8 in megakaryocytes. However, the PACE/furin may influence 
the in vivo activity of cBFVIII. Using the FeCl3 hemostatic challenge to test our 
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BMT/Lenti FPhF8R1645H mice, we show that the incorporation of the R1645H mutation 
into hBFVIII resulted in a significantly more effective variant than any previously 
studied (49) possibly because of its combined increased specific activity with relatively 
high levels of pFVIII. This is the first time in our BMT/Lenti FeCl3 studies that we had to 
perform less chemosclerotic injuries. The cremaster laser injury studies also confirm this 
observation of improved hemostatic efficacy, as the FPhF8R1645H expressing mice had a 
much improved fibrin incorporation in both arteriole and venule injuries.  
 
3.6 Conclusions 
In this section, we provide evidence that the low expression of pcBF8 in megakaryocytes 
during megakaryopoiesis is due to ineffectiveness of FVIII intracellular processing, and 
not because of cBFVIII mRNA levels or stability. We also present evidence that a single 
RH amino acid substitution at hBFVIIIR1645H, a site that is part of the putative 
PACE/furin cleavage site of FVIII, does not affect phBFVIII protein level, but increases 
the activity of hBFVIII in vivo in BMT/Lenti FVIIInull studies. This increased activity was 
associated with increased fibrin incorporation into a growing thrombus and suggest a 
strong candidate to carry forward to dog studies and possibly clinical application. 
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3.7 Future Studies 
3.7.1 Additional Murine Studies of phBFVIIIR1645H 
We need to complete our characterization of the phBFVIIIR1645H mice. We believe that 
our studies suggest that this is a strong candidate for future clinical studies so additional 
analysis in the murine system is appropriate for this construct. We will test PRP from 
these mice for thrombin generation studies, using protocol described in Chapter 2 to 
define the relative fold change in FPhF8R1645H activity to get a better understanding of 
why the R1645H FVIII appears to be so effective. 
To begin to study single chain versus two chain content in platelets of our 
FPhF8R1645H BMT/Lenti FVIIInull mice, we will first address and confirm the expression 
studies from Dr. Arruda’s group (152) using purified hBFVIII and cBFVIII. 25 µg/ml 
total of cBFVIII and hBFVIII protein will be loaded onto a reducing 4–12% NuPage gel 
with Seablue Plus 2 marker (Life Technologies, Bethesda, MD), run at 200V for 50 
minutes and transferred to a nitrocellulose membrane. cBFVIII will be detected using 
the mouse monoclonal antibodies (2 µg/ml total) clone 4B1.2C8 against the heavy chain 
and clone 2C4.1C3 against the light chain (both provided by Dr. Arruda). Detection of 
cBFVIII is with IRDye 800CW rabbit anti-mouse IgG (H&L) (Rockland 
Immunochemicals, Inc., Gilbertville, PA), and scanning is done using on an Odyssey 
Infrared Imaging System (LI-COR Biosciences, Lincoln, NE). hBFVIII studies will be 
done using a sheep polyclonal antibody (1 µg/ml) (Abcam, Cambridge, MA) and detected 
by IRDye 800CW donkey anti-sheep IgG (H&L). We will repeat these studies using 2 x 
107 platelets in total lysate from cF8.24, hF8.38 transgenic mice, and FVIIInull mice as a 
negative control to establish expression levels in platelets. We will then confirm the 
presence of the single chain for the FPhF8R1645H mutant relative to FPhF8 BMT/Lenti 
mice, and compare to the FPcF8 BMT/Lenti mice. We anticipate that as with BHK cells 
that FPhF8R1645H mice will have a higher level of single chain ratio relative to two chain 
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form in their platelets than phBF8 mice though not as much as pcBF8 mice, thus 
providing supportive evidence that hBFVIIIR1645H has a higher specific activity because 
of its single-chain state.  
We will also study embolization and apoptosis studies addressed earlier in the 
BMT/Lenti FPhF8R1645H mice to fully develop our thesis that phBFVIIIR1645H is highly 
effective. Another approach to studying embolization would be to cross our FVIII variant 
transgenic mice onto the apolipoprotein E (ApoE) (145) atherosclerotic mice background 
to look for risks factor of developing atherosclerosis when animals are given a normal 
versus high fat western diet. Based on our fibrin accumulation in the cremaster injury 
model, we expect that our embolization data will show that the number and size of 
emboli after lentiviral gene therapy with FPhF8R1645H will have been normalized and 
represent the first lentiviral construct to show any improvement. We also expect that 
compared to the pcBFVIII mice that phBFVIII mice will have normal platelet count 
recovery and no increase in level of recipient platelet chimerism. These studies will 
support our contention that phBFVIIIR1645H combines the best of both worlds, specific 
activity and expression levels and is worthy to move on to large animal studies. 
 
 
3.7.2 Additional Platelet Recovery pFVIII BMT/Lenti Studies 
While the main focus of our studies is not to define the molecular basis of the poor 
intracellular processing of cBFVIII in murine megakaryocytes, we do think that it will be 
worthwhile to pinpoint the exact site of deficiency in cBFVIII processing as this may 
have clinical implications in future studies of platelet-delivered FVIII and other proteins. 
We propose to do BMT/Lenti studies of pcBFVIII using FPhF8, FPhF8R1645H and FPcF8 
into genetically engineered mice deficient in LMAN1 or MCFD2. In these studies, we 
anticipate that the expression of cBFVIII will have greater difficulties of processing 
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leading to lower levels of each pFVIII and greater cellular death and poorer platelet 
count recovery.  
 
 
3.7.3 pFVIII Studies into a Larger Animal Model 
We believe that we have set the stage to carry our studies to the next phase of studying 
pFVIII in the canine hemophilia A model. This model is the best-studied large animal 
model and unlike mice, these dogs have joint and other soft injury bleeds (58, 86). 
Moreover, given the unusual manner in which FVIII is delivered by the pFVIII strategy 
caution need be exerted before going to clinical trials.  
We have addressed several of the drawbacks to studying pFVIII with FVIIInull dogs, 
and provide evidence that our pFVIII studies can be translated into a canine model of 
hemophilia A (58). First we addressed the issue of pFVIII not being equivalent to plasma 
FVIII despite pFVIII being more effective by using variants of FVIII with increased in 
vitro specific activity. The recent availability of recombinant cBFVIII and our pFVIII 
variant studies with cBFVIII and the cBFVIII PACE/furin site provides new insight into 
the biological activity and in vivo functionality of cBFVIII. These studies suggest that 
cBFVIII is very effective at clot formation in vivo and that cBFVIII reduced the risk of 
clot embolization observed with hBFVIII. Secondly, we have addressed the issue of the 
absence or near absence of vWF in canine platelets (97, 127), and whether this absence 
will affect intracellular processing of FVIII within developing megakaryocytes. We have 
shown in our studies with IR8, that despite IR8 low binding to vWF (134), IR8 is 
effectively targeted to platelet α-granules and released at injured sites (49). In addition 
to this, in our earlier studies we showed that 70% of pFVIII targets to platelets 
independent of vWF (196), and therefore should not affect intracellular processing of 
cBFVIII within the developing megakaryocytes. Moreover, our inhibitor studies of pIR8 
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suggest that IR8 is still effective at injured sites even in the presence of FVIII inhibitors; 
however, we believe that the canine model is a better model to study inhibitor 
development to FVIII.  
For these animal studies we will use mobilized stem cell followed by transduction 
at various MOIs with FPcF8, FPhF8 and FPhF8R1645H lentiviruses. The cells will then be 
grown in culture as described in Chapter 2, with 50 ng/ml human TPO (ProspecBio, 
Rehevot, Israel) in IMDM containing 0.5% PS, 1% LG, 10 µg/ml insulin, 740 µg/ml 
transferrin, 15% FBS, 40 µg/ml low density lipoprotein (Life Technologies, Bethesda, 
MD), 6 ng/ml human IL-3, 10 ng/ml IL-6, and 100 ng/ml of stem cell factor (all Pepro-
Tech Inc., Rocky Hill, NJ). At days 8-10, we will separate high ploidy megakaryocytes 
from the remaining cells by bovine serum albumin gradient (125) for ELISA titers and 
Western blot analysis of cBFVIII and hBFVIII. We anticipate that these studies will show 
similar results to the BHK cells in terms of relative ratios of single-chain to two-chain 
FVIII for cBFVIII and hBFVIII.  
Transduction of canine FVIIInull total hematopoietic cells with the lentiviruses 
will follow a similar protocol to our murine studies and involve determination of optimal 
MOI for transduction of the hematopoietic cells using retronectin-coated plates. Platelet 
and plasma of the various FVIIIs will be measured prior to beginning the BMT and in the 
reconstituted dogs weekly until the platelet count has returned to normal, and then 
monthly for two years. We anticipate from our mice studies that pFVIII antigenic level 
per platelet would be comparable between the total lysate and the agonist-released pool 
for all lentiviral studies supporting α-granular storage of the FVIII, but we will also 
confirm this α-granular localization by immunoelectron microscopy as previously 
described by us (196). Additionally we will examine the dogs for the development of anti-
FVIII antibodies as we propose that pFVIII will be sequestered and will have very low 
immunogenicity.  
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 I anticipate that we will try to use the same dog as the recipient after a standard 
conditioning for a full BMT (104) rather than a less aggressive procedure (83) initially 
since we wish to see efficacy and also test out the effect of low platelet counts on survival. 
My primary endpoint will be spontaneous bleeds compared to dogs similarly treated by 
infusion with empty virus by BMT/Lenti. The Chapel Hill strain of hemophilia A and 
hemophilia B dogs have ~ 5 bleeds/year that require immediate replacement therapy to 
prevent disability or death (51, 151). While it is possible that pFVIII therapy will be 
effective in decreasing spontaneous bleeds, this approach may not able to prevent 
bleeding in a more challenging setting. We propose to study a canine cuticular bleeding 
time that has been described (44). In normal dogs, bleeding usually ceases after 2-8 min. 
In contrast, in hemophilic animals, bleeding continues for up to 20 mins and requires 
cauterization.  
The greatest risk from clot instability in patients with hemophilia A would be an 
increased incidence of pulmonary embolisms (PEs) from deep vein thromboses (DVTs), 
and several DVT/PE dog models have been described including the use of the sclerosing 
agent, and the external application of a FeCl3 solution to a vessel (188). To measure clot 
instability we will follow this aggressive inferior venae cava FeCl3 injury model by 
applying a 20% FeCl3 solution to an exposed femoral vein in these pFVIII/FVIIInull dogs, 
FVIIInull dogs treated with recombinant cBFVIII to the plasma equivalency level seen in 
the pFVIII/FVIIInull dogs, and WT dogs to follow thrombus development and clinical 
signs of PE. 
We will monitor inhibitor formation in these pFVIII/FVIIInull dogs by measuring 
antibody binding by ELISA (152) and by Bethesda titers (152) pre-BMT and post-BMT 
(initially weekly, then monthly and then quarterly). For practical reasons, prolongation 
of the activated partial thromboplastin time in a mixing assay (test plasma + normal 
control plasma at 1:1 dilution or higher) is often used to detect the presence of inhibitory 
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antibodies to FVIII and formal Bethesda titers are measured on selected positive 
samples. In addition, if a dog develops a worsened bleeding diathesis, we will look for the 
presence of an anti-FVIII antibody. To address the importance of the canine FVIII 
PACE/Furin cleavage site in vivo we propose to do comparative functional studies of 
FVIII using 3 Hemophilia A dogs per arm, with hBFVIII as our negative control, cBFVIII 
as our positive control and a cBFVIII variant with the deletion of the PACE/Furin site. I 
anticipate that all these studies will be done with Dr. Timothy Nichols (118) at the 
University of North Carolina, Chapel Hill who is experienced with most of the 
technology, and with the advice as well of Dr. Beverly Torok-Storb (104) at the Fred 
Hutchinson Cancer Research Center who is an expert in BMT/Lenti studies. 
 In the future, I would expect that this strategy would go to actual patient care and 
anticipate that the studies will initially be done in hemophilia A patients with intractable 
inhibitors and major life-threatening complications like intractable bleeds. Then these 
studies will progress to other patients who have less severe clinical complications from 
their inhibitors. 
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